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The prohibitory effects of dietary fiber in colorectal cancer have been 
identified, although the detailed mechanism of this beneficial effect remain 
unclear. Butyrate, a fermentation metabolite of fiber, has anti-cancer properties 
by inhibiting cell proliferation and increasing cell apoptosis in cancer cells. A 
major mechanism, whereby butyrate exerts anti-cancer effects in colorectal 
cancer, is its role as an HDAC inhibitor. Moreover, it has been suggested that the 
metabolic fate of butyrate is significantly related to its role as an HDAC inhibitor. 
Therefore, understanding butyrate metabolism in cancerous colonocytes sheds 
important light on how butyrate has its selective and inhibitory effects toward 
colorectal cancer.  
This dissertation reports (1) colorectal cancer cells exhibit reduced ability 
to oxidize butyrate; (2) the mechanisms of butyrate oxidation are carnitine-
dependent and carnitine-independent in colorectal cancer cells; (3) the Warburg 
effect, inactivation of pyruvate dehydrogenase (PDH), is a critical event to 
repress the carnitine-dependent butyrate oxidation in colorectal cancer cells. 
Also, this dissertation further describes that (1) butyrate suppresses its own 
oxidation by regulating short-chain acyl dehydrogenase (SCAD) levels in 
colorectal cancer cells; (2) butyrate acts as an HDAC inhibitor and (3) selectively 
inhibits HDAC 1 in order to suppress SCAD expression in colorectal cancer cells.  
These findings bridge the important relationship between butyrate 
metabolism and its epigenetic role in order to explain its inhibitory effects in 
colorectal cancer cells. Also, the results raise a key question (Why is butyrate 
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regulation in its own oxidation in colorectal cancer cells?) for future studies that 
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Colorectal cancer (CRC) is the third most commonly diagnosed and mortal 
cancer in the United States (American Cancer Society, 2016). The approximate 
economic burden of CRC including drug therapy is up to $40,000 per month 
(Latremouille-Viau et al., 2016; Meropol & Schulman, 2007). Most risk factors of 
CRC are highly associated with modifiable lifestyles, such as diet, alcohol 
consumption, smoking, physical activity and obesity (Johnson et al., 2013). Of 
these risk factors, dietary factors play a significant role in CRC incidence, and the 
modifications of food patterns might decrease CRC risk up to 70% (Haggar & 
Boushey, 2009).  
The protective function of dietary fiber has been emphasized through 
many epidemiological, clinical and experimental studies, even though it is 
controversial. A diet high in dietary fiber (DF) has a beneficial impact on colon 
health and is proposed to decrease the likelihood of developing (Blackwood, 
Salter, Dettmar, & Chaplin, 2000; Liu, 2003; Mudgil & Barak, 2013; Vargas & 
Thompson, 2012). Currently, the critical roles of the gut microbiota and its 
derived metabolites toward colonic health and CRC development has been the 
main focus in CRC research (Holmes, Li, Athanasiou, Ashrafian, & Nicholson, 
2011; Louis, Hold, & Flint, 2014). DF escapes digestion in the small intestine and 
is metabolized in the colon by gut microbiota (Gropper & Smith, 2012; Tungland 
& Meyer, 2002). Through fermentation, DF gives rise to short chain fatty acids 
(SCFAs) and gases as end-products that have various advantageous roles for 
colonic and host health (Blackwood et al., 2000; Macfarlane & Macfarlane, 2012).  
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Among the microbial-derived metabolites, butyrate plays an important role 
in colonic health and has anti-cancer effects (Havenaar, 2011). Primarily, 
butyrate is the preferred energy substrate for colonocytes and also functions as a 
histone deacetylase (HDAC) inhibitor (Hamer et al., 2008). As an HDAC inhibitor, 
butyrate causes epigenetic modifications of genes involved in cell proliferation, 
apoptosis and differentiation and reduces growth of tumor cells (Leonel & 
Alvarez-Leite, 2012; Tan et al., 2014). However, the obvious opposing roles of 
butyrate in cell proliferation in normal versus cancerous colonocytes has been 
observed and referred to as the “butyrate paradox” (Hague, Singh, & Paraskeva, 
1997; Leonel & Alvarez-Leite, 2012). Recent evidence indicates that the 
metabolic transformation of cancerous colonocytes to utilize more glucose over 
butyrate (the Warburg effect) results in a change of butyrate’s metabolic fate and 
function (Bultman, 2014; Donohoe, Curry, & Bultman, 2013). Also, a more 
complicated role of butyrate in histone acetylation has been described (Donohoe 
et al., 2012). If butyrate is oxidized as an energy source, it is involved in histone 
acetylation as a cofactor for histone acetyltransferase (HAT). However, if 
butyrate is accumulated in the nucleus due to the Warburg effect, it acts as an 
HDAC inhibitor.  
Recent evidence has also shown that reduced gene expression that 
related to mitochondrial metabolism in the tumor tissue from CRC patients might 
bring the change of butyrate metabolism in cancerous colonocytes (Birkenkamp-
Demtroder et al., 2002). For example, short-chain acyl-CoA dehydrogenase 
(SCAD), an enzyme functioning associated with the first step of butyrate 
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oxidation is decreased in CRC. This may allude to a reduced ability in cancerous 
colonocytes to oxidize butyrate, which would also impact the molecule’s 
epigenetic roles. Therefore, a better understanding of mechanisms that regulate 
butyrate oxidation in cancerous colonocytes is necessary to unravel how butyrate 
exerts its selective and inhibitory effects toward colorectal cancer. However, 
there has been less understanding regarding the mechanism of butyrate 
oxidation in cancerous colonocytes and the link between SCAD and butyrate 
oxidation in cancerous colonocytes. 
Thus, this dissertation begins with general information about CRC, the role 
of dietary fiber in CRC, and overall knowledge about butyrate. Chapter II focuses 
on the mechanisms of butyrate oxidation in cancerous colonocytes by 
emphasizing carnitine-dependent oxidation mechanisms. Chapter III focuses on 
butyrate’s function in its own metabolism in cancerous colonocytes by describing 








1.1 Colorectal cancer  
Colorectal cancer (CRC) is one of the most common and deadly cancers 
worldwide, along with lung, breast and prostate cancer (Arnold et al., 2015; 
Siegel, Miller, & Jemal, 2016). In 2016, the American Cancer Society expects 
16% new CRC cases and deaths in the United States (Siegel et al., 2016). The 
causes of CRC are most likely associated with an individual’s lifestyle, which 
includes diet, alcohol consumption, physical activity and smoking (Arnold et al., 
2015; Arnold et al., 2016; Patel & De, 2016). Therefore, an understanding of the 
pathology and risk factors associated with CRC are critical components in the 
fight to decrease CRC incidence and mortality. Section 1 will provide 
comprehensive background about CRC (including a general introduction, 
molecular approach of carcinogenesis and risk factors).  
1.1.1. General Introduction: Definition, Stages and Diagnosis of CRC 
Colorectal cancer is the development of malignant cells in the colon and/or 
rectum (NCI, 2014). The TNM classification of malignant tumors (TNM) classifies 
CRC into four stages (Edge SB et al., 2010): Stage I - cancer has dispersed to 
submucosa and slightly invaded the muscle layer of the colon wall; Stage II - 
cancer has spread throughout the colon wall close to organs but not to lymph 
nodes; Stage III – cancer has dispersed to regional lymph nodes, but not to other 
normal organs; Stage IV- cancer has spread through blood and lymph circulation 
to distant organs.  
6 
 
Currently, various screening methods are used to diagnose and prevent 
CRC, and these methods can be used differently based on the CRC stages (Burt 
et al., 2013; Kuipers, Rösch, & Bretthauer, 2013). For early detection, fecal occult 
blood test (FOBTs) and fecal immunochemical test (FITs) can be applied, and a 
positive result from either test will lead to further screening, such as a 
sigmoidoscopy and colonoscopy. Another current tool for CRC diagnosis, 
involves the analysis of molecular biomarkers in a fecal samples, reflecting the 
mechanisms of malignant cells (Imperiale et al., 2014).   
1.1.2. Molecular Development of CRC: Vogelgram of CRC  
Colorectal cancer serves as an important disease model for understanding 
tumor progression and metastasis since gradual changes in phenotype are 
associated with known genetic alterations (Yeatman & Chambers, 2003). 
Therefore, insight into how molecular and metabolic alterations occur during the 
development of the disease may uncover novel treatment strategies or aid in 
CRC prevention.  
In the large intestine, a monolayer of epithelial cells (i.e. stem cells, 
proliferating cells, and differentiated cells) makes up the basic colonic structural 
unit called the crypt. Stem and proliferating cells cover the bottom of the crypts, 
while differentiated cells are found in the upper two-thirds (Riccardo Fodde, 
Smits, & Clevers, 2001). CRC originates at this epithelium-layer of the mucosal 
crypts. Aberrant crypt foci (ACF) are the initial sign of colorectal neoplasia. Due 
to its ability to encircle other crypts, including normal and/or dysplasia cells, ACF 
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promotes the formation of a polyp (Riccardo Fodde et al., 2001). The 
adenomatous (dysplastic) polyp is a tumor that protrudes into the lumen of the 
colon causing an aberrant inter- and intracellular structure, but most ACF or 
adenomas never become cancerous (Riccardo Fodde et al., 2001). Additional 
genetic alterations in oncogenes and tumor-suppressor genes are required to 
develop neoplasia at the level of ACF and drive its further development into what 
would be considered cancerous (Markowitz & Bertagnolli, 2009).  
The Vogelgram is a model of tumor progression to CRC that provides a 
better understanding of the molecular and genetic phenomenon, which occur in 
CRC development. This model addresses the relationship between acquired 
genetic mutations and the progression of CRC (Bellacosa, 2003). The mutations 
occur in genes involved in cell proliferation, differentiation and survival that lead 
to phenotypic changes needed to convert regular epithelium into an adenoma 
and eventually a carcinoma (Bellacosa, 2003). The Vogelgram representation of 
CRC is composed of four main genetic mutations as well as associated signaling 
pathways to yield each event in CRC development and includes adenomatous 
polyposis coli (APC), K-Ras, SMAD 2 and 4, and TP53 (Figure 1) (Bellacosa, 
2003; R Fodde, 2002; Riccardo Fodde et al., 2001; Goel & Boland, 2012; 
Markowitz & Bertagnolli, 2009; Perše & Cerar, 2014). First, the adenomatous 
polyposis coli (APC) is a tumor-suppressor gene, and its mutation is the most 
common event in the initiation of CRC. APC is necessary to activate the β-
catenin/Wnt signaling pathway which removes extra intracellular β-catenin and 
inhibit its movement into nucleus; hence, without functional APC, β-catenin/Wnt 
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signaling pathway is inappropriately activated. Thus, β-catenin is not degraded 
and moves to the nucleus, where it drives transcription of genes that promote the 
cell cycle, such as DNA-binding proteins of the T-cell factor (TCF) family resulting 
in gene transcription. The second major mutation occurs in K-Ras, which is an 
oncogene that, when mutated, plays a role in the promotion by activating 
mitogen-activated protein kinases (MAPK) pathway to increase cell proliferation 
and decrease apoptosis. The synergetic action between abnormal APC and K-
Ras is required to form large adenomas in CRC. SMAD 2 and 4 are pivotal 
tumor-suppressor genes belonging to the growth-suppressing transforming 
growth factor β (TGFβ) pathways, which results in slowing cell growth. Therefore, 
mutations in these two genes play a role in the malignant transformation and 
expansion of CRC. Lastly, TP53 is another critical tumor-suppressor gene in 
CRC development. Inactivation of p53 leads to the loss of checkpoint for DNA 
damage during the cell cycle after G phase, increasing proliferation and reducing 
apoptosis and promoting malignant tumorigenesis. The most important thing to 
understand about the development and progression of CRC is that it is not a 
mutation in any single gene, but a combination of all of them that drives the 
disease.  
1.1.3. Risk Factors of CRC  
The risk factors of CRC include demographic factors (age and gender), 
medical conditions (family history, individual history with inflammatory bowel 
disease (IBD) and metabolic diseases), lifestyle-related factors (physical activity, 
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smoking and alcohol consumption) and dietary factors (Figure 2). Behavioral and 
environmental modification in lifestyle-related factors such as diet has been 
suggested to influence CRC incidence.   
1.1.3.1. Age 
According to the National Cancer Institute (NCI), incidence of CRC 
increases after the age of 40 (45-54 years: 12.0%) as compared to those under 
40 years old (20-24 years: 1.1%, 35-44 years: 3.8%). The likelihood of CRC 
occurrence rises aggressively after the age of 50 (55-84 years: 71.1%, +84 
years: 12.1%) (Horner et al., 2009). Even though the age of 50+ is an apparent 
risk factor for CRC, current incidence and mortality has been decreasing in 
recent years in these populations due to the early detection by routine 
colonoscopy (Zauber et al., 2012). This trend holds true for other countries that 
have adopted colonoscopy as a primary screening tool (Kaminski et al., 2010; 
Patel & De, 2016).   
Conversely, an increasing trend for CRC is being observed in the younger 
population (20-49 years) (Ahnen et al., 2014; O'Connell, Maggard, Liu, & Etzioni, 
2003). The incidence of CRC has been rising, and becoming one of the most 
commonly diagnosed cancers in this age group (Fairley et al., 2006). This 
upward pattern among younger generation may be due to the fact that they are 
not generally recommended for screenings of CRC despite their high risk from 
consuming a Westernized-diet (Patel & De, 2016; Yusof, Isa, & Shah, 2012). 




The impact of gender on CRC incidence and mortality has not been 
clearly established. However, considering gender as a risk factor along with age, 
excess body weight and obesity, there have been higher positive associations 
with males in CRC incidence compared to females. Many studies have reported 
that men have higher rates of CRC incidence and mortality (age-adjusted) 
compared to women (Brenner, Hoffmeister, Arndt, & Haug, 2007; Brenner, 
Hoffmeister, & Haug, 2008; Matanoski, Tao, Almon, Adade, & Davies‐Cole, 
2006). In addition, the correlation between gender (age-adjusted) and advanced 
neoplasia in the colon presents that men have a greater risk for advanced 
colorectal neoplasia across all age groups than women (Nguyen, Bent, Chen, & 
Terdiman, 2009). Epidemiological studies also report that the risk of CRC in 
overweight or population with high body mass index (BMI) was significantly 
higher in males compared to females (Brändstedt et al., 2012; Johnson et al., 
2013). The reason for the gender differences is still unclear, but the differences in 
genetic background, hormones and fat distribution between male and female 
have been suggested as rationales for gender-dependent differences (E 
Giovannucci, 2002; McMichael & Potter, 1980; Press et al., 2008). In our studies, 
HCT116 colorectal cancer cells represent an in vitro model that is routinely used. 





1.1.3.3. Family history 
Approximately 20% of CRC cases come from the patients who have a 
previous family history of this disease (Fund & Research, 2007; Haggar & 
Boushey, 2009). This signifies the important genetic component associated with 
CRC development. The susceptibility of CRC is increased up to 8 times in a first-
degree relative (i.e. parents, siblings, or offspring) (Haggar & Boushey, 2009; 
Johns & Houlston, 2001; Johnson et al., 2013). Moreover, sibling risks are higher 
than parent-offspring risks (Carstensen, Soll‐Johanning, Villadsen, Søndergaard, 
& Lynge, 1996; Maire et al., 1984). Since early onset of CRC is mainly derived 
from genetic alterations, the reasonable explanation for this strong correlation 
between family history and CRC can be attributed to gene inheritance patterns 
(Haggar & Boushey, 2009). In conjunction with genetic inheritance, communal 
environments among family members also contributes to CRC (Slattery, 2000).  
1.3.3.4. Individual History: Inflammatory Bowel Disease  
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and 
Crohn’s disease, is considered as a predisposing risk factor for CRC (Haggar & 
Boushey, 2009). UC is a chronic disease characterized by inflammation and 
colonic/rectal ulcers and Crohn’s disease is also associated with inflammations; 
however, it can occur in any part of the gastrointestinal tract (GI) (NDDIC, 2013; 
NIDDK, 2014). The overall risk of developing CRC in IBD patients relies on the 
duration, age of onset, and the severity of the disease (Haggar & Boushey, 2009; 
Johnson et al., 2013; Mellemkjæ r et al., 2000). Therefore, patients who are 
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diagnosed with IBD are recommended to have regular CRC screenings (Haggar 
& Boushey, 2009; Munkholm, 2003). For example, an early finding of IBD with 
colonoscopy screening reduces CRC incidence (Eaden, Abrams, Ekbom, 
Jackson, & Mayberry, 2000). In addition, treatment with 5-aminosalicylic acid (5-
ASA) decreases CRC incidence among IBD patients (Munkholm, 2003). Thus, 
early detection and treatment of IBD can reduce its progression to CRC. It is 
important to recognize that IBD does not cause CRC (i.e. not an initiator), but 
rather is a promotor becoming the chronic through evaluated inflammatory 
environment.  
1.3.3.5. Metabolic Disease: Obesity and Diabetes 
Obesity is a critical risk factor that increases the prevalence of other 
metabolic diseases such as type II diabetes, hypertension and cardiovascular 
disease (Eckel, Grundy, & Zimmet, 2005). In addition, there is ample evidence 
that indicates that obesity is strongly correlated with the pathology of certain 
cancers, and a risk factor for colon cancer (Calle & Kaaks, 2004). According to 
epidemiological studies, a greater body mass index (BMI) and waist 
circumference (WC) are positively linked with CRC (Ma et al., 2013; Patel & De, 
2016). For instance, individuals who have a BMI less than 25 (BMI ≤ 25kg/m2) 
have a lower likelihood of CRC development compared to those with BMI greater 
than 30 (BMI ≥ 30kg/m2) (Huxley et al., 2009). Although the role of obesity in 
CRC incidence is not fully understood, abnormal metabolic changes including 
insulin resistance, leptin resistance and chronic inflammation have been 
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identified as underlying factors that promote the positive association between 
obesity and CRC (Ma et al., 2013).  
Along with obesity, diabetes is a metabolic disease that has been 
correlated with CRC development (Flood, Strayer, Schairer, & Schatzkin, 2010; 
Huxley et al., 2009). For example, people with diabetes have a 19% higher risk of 
developing CRC compared to non-diabetics (He et al., 2010). Although the 
mechanistic link between diabetes and CRC is unclear, hyperinsulinemia is 
considered a direct causal factor due to the role insulin and insulin growth factor-
1 (IGF-1) have in tumor cell proliferation (Deng, Gui, Zhao, Wang, & Shen, 2012; 
Edward Giovannucci et al., 2010). It is difficult to establish the separate 
contributions from obesity and diabetes as risk factors for CRC due to their direct 
influence on each other.  
1.3.3.6. Lifestyle-related Factors: Physical activity, Smoking and Alcohol 
Consumption  
Lifestyle-related factors that impact the development of CRC include 
physical activity, smoking and alcohol consumption (Haggar & Boushey, 2009). 
Since these factors are modifiable, any knowledge toward how each contributes 
in CRC development is pivotal in prevention.  
First, participating in physical activity reduces the likelihood of developing 
CRC (Haggar & Boushey, 2009; Johnson et al., 2013). When participating in 
regular physical activity, the risk of CRC is decreased by 24% (Wolin, Yan, 
Colditz, & Lee, 2009). Several physiological mechanisms on how regular physical 
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activity attenuates CRC incidence have been suggested, but are still not clearly 
understood (Haggar & Boushey, 2009; Harriss et al., 2009; Wu, Paganini-Hill, 
Ross, & Henderson, 1987). These mechanisms include improvement in body 
weight or BMI, improvement in insulin sensitivity, elevation of metabolic rate 
(includes increase in metabolic efficiency) and enhanced GI tract motility. 
Moreover, the frequency and intensity of physical activity to prevent CRC 
development is important (Haggar & Boushey, 2009). For example, the American 
Cancer Society (ACS) suggests at least 150 min of physical activity per week in 
order to reduce CRC (Grimmett, Simon, Lawson, & Wardle, 2015; Kushi et al., 
2012).  
Smoking has been known as the primary risk factor for lung cancer, but 
many studies also established a positive association between smoking and CRC 
(Haggar & Boushey, 2009; Johnson et al., 2013; Patel & De, 2016). A meta-
analysis reports that 20% of smokers have an elevated risk for CRC in 
comparison with people who have never smoked (Tsoi et al., 2009). In addition, 
the frequency of smoking plays a role in CRC risk. Johnson et al. (2013) found 
an 11% increased risk of CRC from smokers with 17 cigarettes/month and 21% 
increased risk in CRC from smokers with 34 cigarettes/month compared to non-
smokers (Johnson et al., 2013). The effects of smoking on CRC may be 
explained by the carcinogens produced from cigarettes which accelerate tumor 




Like smoking, alcohol consumption is associated with an increased 
incidence of CRC. The frequency and quantity of alcohol consumption are also 
significantly related to CRC development (Haggar & Boushey, 2009; Wu et al., 
1987). For example, the relative risk (RR) for CRC when consuming 10, 50, and 
100 g/day alcohol consumption was 1.07, 1.38 and 1.82, respectively (Moskal, 
Norat, Ferrari, & Riboli, 2007). Heavy alcohol consumption may result in 
carcinogen formation in colon, failure in DNA repair and inefficient absorption of 
nutrients in the colon, making cells vulnerable to tumor formation and CRC (Fund 
& Research, 2007; Haggar & Boushey, 2009).  
In summary, regular physical activity, smoking cessation, and limiting 
alcohol consumption are strongly suggested to prevent CRC development and 
reduce mortality. 
1.3.3.7. Dietary Factors 
Dietary factors strongly impact CRC development because dietary factors 
can act as pro- and/or anti- cancer factors at any point in the multiple stages of 
CRC pathology (Vargas & Thompson, 2012). Thus, dietary factors can be utilized 
successfully to decrease the CRC incidence and progression (Haggar & 
Boushey, 2009; Vargas & Thompson, 2012).  
Convincing dietary factors include red and processed meat, dietary fibers 
and whole grains. High consumption of red and processed meat is a high risk 
factor for CRC (Chan et al., 2011; Edward Giovannucci et al., 1994). Chan et al. 
(2001) observed that the risk of CRC elevated by 29% for every 100 g/day of red 
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meat intake and 21% for every 50 g/day of processed meat consumption (Chan 
et al., 2011). In addition to the amounts of consumption, the frequency of red and 
processed meat intake also increase the risk of CRC development by 13% and 
9% for five servings per week respectively (Johnson et al., 2013). Moreover, the 
cooking temperature and time of red and processed meat is also partially 
involved in the risk of CRC incidence (de Verdier, Hagman, Peters, Steineck, & 
Ö vervik, 1991). The potential mechanisms involved in CRC development have 
been found to involve the natural (heme) and artificial (nitrite-preserve) 
containing DNA-damaging N-nitroso compounds that occur in both red meat and 
processed meat (Babbs, 1990; Cross, Pollock, & Bingham, 2003; Santarelli, 
Pierre, & Corpet, 2008). The N-nitroso compounds have a direct cytotoxic and 
genotoxic impacts on the epithelium layer of colon and increase lipid peroxidation 
to promote colorectal tumorigenesis (Bastide et al., 2015; Bastide, Pierre, & 
Corpet, 2011). 
There is ample evidence that demonstrates low consumption of dietary 
fiber increases the risk of CRC (Aune, Chan, et al., 2011; Park et al., 2005). For 
instance, low fiber intake (<10 g/day) increases the risk of CRC by 18% 
compared to higher intake (10-15 g/day) (Park et al., 2005). In addition, in 
reference to dietary fiber components, whole grains have a negative association 
with CRC incidence (Aune, Chan, et al., 2011; Jacobs Jr, Marquart, Slavin, & 
Kushi, 1998; Schatzkin et al., 2007). A meta-analysis using case-control 
publications found that high consumption of whole grains reduced the risk of 
CRC incidence by 20% (Jacobs Jr et al., 1998). The next section (1.2 The role of 
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dietary fibers in CRC) will discuss the relationship between dietary fibers and 
CRC in more detail, which will include the epidemiological findings and its 
underlying mechanisms that maybe involved in CRC prevention.  
Limited, but suggestive dietary factors that impact CRC development 
include high-fat diets and low intake of fruits and vegetables. Various studies 
report that consuming a diet high in overall/total fat, saturated fat and animal fat 
increase CRC development (T. T. Fung et al., 2010; Graham, Dayal, Swanson, 
Mittelman, & Wilkinson, 1978). However, in other studies, there was no 
association between fat intake and CRC (Alexander, Cushing, Lowe, Sceurman, 
& Roberts, 2009; Edward Giovannucci et al., 1994). Importantly, because of the 
inconsistent findings in epidemiological studies, it is difficult to define the 
contribution of dietary fat content toward CRC incidence. However, a high intake 
of fat increases the total energy intake and the likelihood of obesity that is 
significantly associated with CRC (GRAHAM et al., 1988; Ma et al., 2013). It has 
been demonstrated that saturated fatty acids increase inflammation, change bile 
acid metabolism, and colon environments, which leads to an elevated risk for 
CRC development (Mathias & Dupont, 1979; Van Eldere, Celis, De Pauw, 
Lesaffre, & Eyssen, 1996).  Therefore, lower consumption of saturated fat and 
animal fat is suggested to prevent CRC incidence.  
Overall epidemiological studies regarding the relationship between fruit 
and vegetable intake and CRC incidence suggests there is an inverse correlation 
(Johnson et al., 2013; Patel & De, 2016). High intake of fruits and vegetables 
decreased the risk of CRC (Aune, Lau, et al., 2011). These findings were 
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controversial since other studies found no association between fruits and 
vegetables intake and CRC (van Duijnhoven et al., 2009). Although the beneficial 
effects of fruits and vegetables consumption on CRC incidence are still not 
clearly established, many experimental studies found that bioactive compounds 
and antioxidants in fruits and vegetables have anti-inflammatory, anti-cancer and 
tumor-suppressive effects (Liu, 2003; Steinmetz & Potter, 1996; Vanamala et al., 
2006). Therefore, the intake of fruits and vegetables is recommended to reduce 
the incidence and mortality of CRC.  
In conclusion, dietary factors play an important role in CRC incidence. In 
addition, because dietary factors can be manipulated, it is important to implement 
public awareness and intervention. Therefore, based on the findings from the 
epidemiological and clinical studies, Figure 3 describes dietary recommendations 
in order to prevent CRC incidence. 
 
1.2 Role of Dietary Fiber in CRC 
Although advancements in technology related to detecting CRC have 
lowered CRC incidence, it is still the third deadliest cancer in the United States 
(Kahi, Imperiale, Juliar, & Rex, 2009; Siegel et al., 2016). As described in section 
1, dietary factors are important in decreasing CRC incidence, slowing 
progression and aiding in prevention (Vargas & Thompson, 2012). Although 
controversial, the importance of dietary fiber (DF) in CRC incidence has been 
established through many epidemiological studies (Baena & Salinas, 2015; Park 
et al., 2005; Romaneiro & Parekh, 2012; Trock, Lanza, & Greenwald, 1990). 
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However, special attention has been devoted to the relationship between CRC, 
DF, and the functions of the gut microbiota (Davis & Milner, 2009; Sears & 
Garrett, 2014; Zackular et al., 2013). For example, the metabolism of DF through 
the gut microbiota is highly associated with colonic health, the development of 
CRC, and the general health of an individual (Cani & Delzenne, 2009; Sekirov, 
Russell, Antunes, & Finlay, 2010). Section 2 will present a general introduction of 
DFs as well as a summary of previous studies regarding the role of DFs in CRC 
incidence. In addition, the general information for gut microbiota and its roles in 
CRC will be described. 
1.2.1. General Introduction: Definition, Classification and Physiological 
roles of DF  
It is difficult to describe a single, simple definition of DF because there is 
no standard definition and it varies between organizations (Table 1). According to 
current definitions, the term ‘dietary fiber’ compromises a broad spectrum of 
information on DF from the sources (plants and animal substances), chemical 
properties, and physiological effects to origin (natural and synthesized). These 
diverse definitions of DF can be problematic due to their inability to provide 
unified guidelines for DF in food labeling, references of nutrients values, and 
health claims (Cummings, Mann, Nishida, & Vorster, 2009). In 2008, the Codex 
Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) 
addresses ‘an agreed definition’ of DFs in order to impose a more clear standard 
(Table1). (Alimentarius, 2008). 
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Dietary fiber come from natural and/or artificial sources. As listed in Table 
2, naturally-occurring DF includes indigestible-polysaccharides (non-starch 
polysaccharides, cellulose, hemicellulose, pectin, β-glucans, gums and 
mucilages), resistant oligosaccharides (inulin and fructo-oligosaccharides), 
analogous carbohydrates (resistant -starch and -dextrin), lignin, constituents of 
plants (suberin, waxes and cutin), algal materials, and animal substances (chitin, 
chitosan, collagen and chondroitin). Artificial DF include resistant 
oligosaccharides (fructo-oligosaccharides and galacto-oligosaccaharides) and 
analogous carbohydrates (resistant -starch and -dextrin, modified cellulose and 
polydextrose) (Gropper & Smith, 2012; Mudgil & Barak, 2013; Tungland & Meyer, 
2002). The general classifications of DF rely on their origins and/or 
physicochemical properties (Table 3) (Blackwood, Salter, Dettmar, & Chaplin, 
2000; Joanne Slavin, 2013; J. L. Slavin & Lloyd, 2012; Tungland & Meyer, 2002). 
However, some studies classify DF based on their physiological effects and their 
physicochemical properties (J. L. Slavin & Lloyd, 2012). Physicochemical 
properties of DF include solubility, viscosity and fermentability, and each of these 
properties is commonly associated with each other (Gropper & Smith, 2012; 
Raninen, Lappi, Mykkänen, & Poutanen, 2011; Tungland & Meyer, 2002). For 
example, soluble fiber is more likely to have high viscosity and fermentability; 
whereas insoluble fiber has relatively low viscosity and poor and/or partial 
fermentability (Table 3).  
Major physiological effects of DF can be described as: improvements of 
blood lipid and glucose levels, laxation, overall improvement of colonic health 
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and decreased CRC development (Anderson et al., 2009; Blackwood et al., 
2000; Gropper & Smith, 2012; Kendall, Esfahani, & Jenkins, 2010; Mudgil & 
Barak, 2013; Raninen et al., 2011; J. L. Slavin & Lloyd, 2012; Tungland & Meyer, 
2002). Figure 4 shows the physiological effects of DF and their underlying 
mechanisms.  In addition, many studies demonstrate that DF have a beneficial 
impact on cardiovascular disease, diabetes, and body weight, and appetite 
(Anderson et al., 2009; Kristensen & Jensen, 2011; Joanne Slavin, 2013; J. L. 
Slavin, 2005).  
According to the Institute of Medicine (IOM), an adequate intake (AI) of DF 
is 14 g of fiber/1000 kcal from age one and above (J. L. Slavin & Lloyd, 2012; 
Stipanuk & Caudill, 2013). The conversion of AI is based on median energy 
intake and is equal to 25 g/day for women and 38 g/day for men ages 19- 50 
years (Stipanuk & Caudill, 2013). However, the current average DF consumption 
of Americans is ~ 15 g per day, which fails to meet the AI levels (JL Slavin, 
2008). Therefore, food choices is pivotal in order to meet the recommended 
levels of DF and reduce the risk of chronic disease such CRC. Foods rich in fiber 
that help meet the AI levels  include whole grains, legumes, fruits and vegetables 
(Stipanuk & Caudill, 2013).  
1.2.2. A Summary of Previous Studies: The Roles of DF in CRC 
Although DF have diverse physiological roles, there has been a large 
focused on the effects of DF on general colonic health, which may aid in the 
decrease in CRC incidence (Figure 4). In the last decade, epidemiological 
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studies have indicated that high intakes of DF prevent CRC, but some studies 
have suggested that there is no and/or weak association between DF intake and 
CRC risk (Anderson, Smith, & Gustafson, 1994; Baena & Salinas, 2015; Howe et 
al., 1992; Park et al., 2005). Moreover, the correlation between the intake of DF 
and CRC depends on which variables are applied such as age and/or sources of 
DF. Table 4 summarizes these epidemiological studies regarding the intake of 
DF and its impact on CRC incidence (Aune, Chan, et al., 2011; Bingham et al., 
2003; Dahm et al., 2010; Fuchs et al., 1999; Howe et al., 1992; Mai et al., 2003; 
Michels et al., 2000; Park et al., 2005; Terry et al., 2001; Trock et al., 1990). 
Based on evidence regarding an inverse relationship between DF and CRC, 
studies are categorized as protective effects’; ‘no and/or weak association’; or 
‘changeable depending on variables’.  
Discordant associations from previous publications may be due to several 
reasons. For example, limitations of epidemiological studies include: potential 
bias and confounders, such as the measurement of DF consumption; interactions 
with other nutrients; and potential influences from lifestyle factors such as 
smoking, physical activity, and body weight (Baron, 2005). Other conflicting 
results may be due to study design, such as population size and the follow-up 
period (Baron, 2005; Lawlor & Ness, 2003; Romaneiro & Parekh, 2012). In 
addition, multiple definitions and classification of DF across studies complicate 
the findings (Potter, 1990). Overall, the differences in DF sources in these 
studies make it difficult to generate consistent associations between DF and 
CRC risk (Potter, 1990; Romaneiro & Parekh, 2012; Terry et al., 2001). Other 
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variables include genetic background and the community of gut microbiota, which 
may contribute to conflicting findings from the epidemiological studies (Lozupone, 
Stombaugh, Gordon, Jansson, & Knight, 2012). For example, a change of gut 
microbiota structure by diet is associated with CRC development (Ahn et al., 
2013; Sobhani et al., 2011). Moreover, the differences in gut microbiota between 
healthy and CRC subjects indicate the important roles of gut microbiota in CRC 
risk (Clemente, Ursell, Parfrey, & Knight, 2012). Therefore, failure to consider gut 
microbiota differences in the subjects can cause discordant results.  
1.2.3. Gut Microbiota: Definition, Physiological Functions and Importance 
Microbiota, microflora and normal flora are all terms to describe the 
gathering of microorganisms (bacteria, archaea, viruses, and unicellular 
eukaryotes) living in the human body (Sekirov et al., 2010). The majority of 
microbiota is composed of bacteria in the human body, and most of them 
colonize in the gastrointestinal tract (GI), especially the colon. These organisms 
have been defined as gut microbiota. Through the Human Microbiome Project 
(National Institutes of Health, 2008), the composition and functions of gut 
microbiota have been identified and characterized (Gill et al., 2006; Peterson et 
al., 2009). Approximately 1000 different species of bacteria exist in the colon, 
and these bacteria produce saccharolytic enzymes that metabolize undigested 
nutrients (Joanne Slavin, 2013; Tungland & Meyer, 2002). DF such as pectin, 
guar gum, fructo-oligomers, and resistant starch are the primary substrates for 
this fermentative metabolism by colonic bacteria (Blaut, 2002; Tungland & Meyer, 
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2002). These are fermented into various end-products such as short chain fatty 
acids (SCFAs; acetate, propionate and butyrate) and gases (H2, CO2 and CH4) 
which impact various physiological mechanisms to maintain host health (Holmes, 
Li, Athanasiou, Ashrafian, & Nicholson, 2011; Kinross, Darzi, & Nicholson, 2011; 
Macfarlane & Macfarlane, 2012). For example, the metabolites produced by gut 
microbiota help maintain epithelial homeostasis, regulate lipid metabolism, 
promote nutrient digestion and absorption and mediate immune-cell development 
(Holmes et al., 2011). Figure 5 describes the effects of bacterial-derived 
metabolites and their underlying mechanisms (Blackwood et al., 2000; 
Macfarlane & Macfarlane, 2012; Sekirov et al., 2010; Joanne Slavin, 2013).  
Current publications support the notion that SCFAs orchestrate the central 
effects of gut microbiota for host and colonic health. Acetate (C2), propionate 
(C3) and butyrate (C4) are the major SCFAs produced by bacterial-fermentation 
in the colon with concentrations ranging from 60 to 150 mM in humans 
(Cummings, Pomare, Branch, Naylor, & Macfarlane, 1987; Nordgaard & 
Mortensen, 1994). SCFAs are involved in both host energy metabolism and 
colonic homeostasis as a major energy source. Acetate and propionate are 
absorbed and transported to the liver and other tissues for metabolism to ATP 
(Blaut, 2002). Butyrate is directly absorbed by colonic epithelial cells and utilized 
as the primary energy source for colonocytes (Donohoe et al., 2011; Hague, 
Singh, & Paraskeva, 1997; Hamer et al., 2008). Additionally, colonic bacteria can 
utilize their self-produced SCFAs as energy sources. Therefore, SCFAs 
produced by gut microbiota are associated with the structural and homeostatic  
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balance that is an important component toward achieving a healthy colonic 
environments (Topping & Clifton, 2001). Since SCFAs are weak acids, they lower 
intestinal pH resulting in a decrease risk of CRC incidence (Hamer et al., 2008; 
Tungland & Meyer, 2002). Lower intestinal pH leads to diminished 
carcinogenesis via altered bile acid metabolism, peptide degradation, and 
formation of toxic compounds in the colon.   
Extensive research has been conducted to identify the contributions of 
specific colonic microbe/microbial groups or microbial-derived molecules to host 
health and diseases (Kinross et al., 2011; Sekirov et al., 2010). Kinross et al. 
(2011) mentioned that gut microbiota have been directly associated with multiple 
diseases including circulatory disease, obesity, IBDs and CRC. Therefore, an 
interruption of colonic- and gut microbial-homeostasis is significantly related to 
the development of those diseases (Kinross et al., 2011). Factors that change 
gut microbiota and its resulting metabolites are the host’s physiological status 
(age, stress, health condition and genotype), diet (high-fat and DF) and 
environmental conditions, such as antibiotic therapy (Figure 6) (Blackwood et al., 
2000; Joanne Slavin, 2013). Of these factors, the role of diet is the most critical 
since diet directly influences the composition of gut microbiota and the production 
of microbial-derived metabolites (Scott, Gratz, Sheridan, Flint, & Duncan, 2013). 
A high-fat diet decreases total gut microbial levels and increases Gram-negative 
bacteria (Holmes et al., 2011). In addition, dietary fructose-oligomer and -polymer 
beneficially alter the bacterial compositions by increasing Bifidobacteria, whereas 
resistant starch prompts the growth of anaerobic Clostridia (Jaskari et al., 1998; 
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May, Mackie, Fahey, Cremin, & Garleb, 1994). Distinct DFs have different effects 
on the composition and quantity of bacterial-derived metabolites. For instance, 
guar gum generates the highest levels of total SCFAs compared to other DF, 
while ispaghula produces higher level of butyrate rather than other SCFAs 
(Blackwood et al., 2000).  
In conclusion, gut microbial homeostasis is a significant factor in 
maintaining a healthy colonic environment, which in turn decreases the risk of 
CRC. Diet plays a critical role in helping determine gut microbiota and 
maintaining this colonic homeostasis.  
1.2.4. Gut Microbiota and CRC 
Accumulating findings emphasize the involvement of gut microbiota in 
CRC development through physiological mechanisms resulting from microbial-
derived metabolites and from an alterations of metabolic composition (Holmes et 
al., 2011; Kinross et al., 2011).  
First, the structure of gut microbiota contributes to the etiology of CRC 
(Hagland & Søreide, 2015; O'Keefe, 2008). For example, alterations in the 
diversity and number of gut microbiota provide possible mechanisms to develop 
CRC (Figure 6). These mechanisms include the production of bacterial-derived 
carcinogenic metabolites, increases in disadvantageous bacteria (ex. 
Streptococcus spp., Escherichia Coli, Fusobacterium nucleatum, Clostridium and 
Bacteroides) and decreases in beneficial species (ex. Bactobacillus) (O'Keefe, 
2008; Sobhani et al., 2011). According to Louis et al. (2014), particular 
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pathogenic bacteria (ex. Clostridium difficile, Fusobacterium spp., and 
Campylobacter spp.) promote CRC development via pro-inflammatory 
interactions with mucosal tissues, such as reactive oxygen species (ROS) 
production and subsequent DNA damage (Louis, Hold, & Flint, 2014). In addition, 
elevation of sulfur-reducing bacteria (Desulfovibrio Vulgaris) accompanied by 
high meat consumption yields carcinogenic compounds such as hydrogen 
sulfide, which causes DNA damage, mucosal inflammation, and cell death 
(Bultman, 2014a; O'Keefe, 2008). Hence, understanding the functions of 
individual bacteria and the potential carcinogenic metabolites produced by these 
bacteria during physiological conditions is pivotal in preventing CRC (Sears & 
Garrett, 2014; Sobhani et al., 2011).  
Next, as mentioned in the previous section, gut microbiota plays a 
significant role in colonic- and microbial- homeostasis through the production of 
metabolites that reduce CRC development (Figure 5). More than any other 
bacterial-derived metabolites, butyrate has been highlighted as a tumor-
suppressive molecule due to its specialized biochemical role (Davie, 2003; 
Havenaar, 2011; Tong, Yin, & Giardina, 2004). By acting as a histone 
deacetylase inhibitor (HDACi), butyrate suppresses cell proliferation and 
increases apoptosis in CRC in vivo and in vitro (Donohoe, Collins, et al., 2012; 
Hague et al., 1993; Holmes et al., 2011; Macfarlane & Macfarlane, 2012). 
Interestingly, the overall reduction of butyrate-producing bacteria (ex. Roseburia, 
Fecalibacterium prausnitzii, and Eubacterium rectale) has been observed when 
comparing the fecal and tissue samples from healthy individuals and CRC 
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patients (Balamurugan, Rajendiran, George, Samuel, & Ramakrishna, 2008; 
Bultman, 2014a; Chen et al., 2013; Wang et al., 2012). In the next section (1.3 
Butyrate), a more comprehensive review on butyrate, its functions, and its 
metabolism in both normal and CRC conditions will be addressed.  
A diet intervention, particularly including DF and/or pre/probiotics, 
improves the community of gut microbiota and SCFAs production leading to the 
amelioration of tumor size and numbers in CRC progression (Chen et al., 2013; 
Davis & Milner, 2009; Zackular et al., 2013). Prebiotics and probiotics block the 
detrimental effects of gut microbiota and the potential carcinogenic mechanisms 
by introducing beneficial living bacteria strains (probiotics) or substrates 
(prebiotics) (Bultman, 2014a; Geier, Butler, & Howarth, 2006). In conclusion, 
targeting certain pathogenic bacteria and improvement of bacterial composition 
through the probiotic or prebiotics represents a promising preventative strategy 
toward CRC.  
 
1.3 Butyrate 
The gut microbiota produces diverse metabolites, resulting from the 
fermentation of DFs. Of these metabolites, special attention has focused on 
SCFAs due to their contributions in the maintenance of microbiota structure and 
colonic health (Figure 5). In particular, butyrate functions as the primary energy 
source for colonic epithelial cells and acts as an HDACi to regulate cell 
proliferation, apoptosis and differentiation (Davis & Milner, 2009; Havenaar, 
2011). However, butyrate has the ability to impose contrasting effects on 
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cancerous colonocytes compared to normal colonocytes. This has been referred 
to as the ‘butyrate paradox’ (Bultman, 2014a; Leonel & Alvarez-Leite, 2012). 
Section 3 will provide more information regarding the origination of butyrate, its 
functions and metabolism, and explanations for the butyrate paradox.    
1.3.1. Butyrate: Synthesis and Functions  
In the colon, several bacteria species are responsible for synthesizing 
butyrate and are divided into two main groups according to enzymes in the last 
steps of their butyrate production pathway (Flint, Duncan, Scott, & Louis, 2015). 
Butyrate is produced by bacteria employing either butyryl-CoA: acetate-CoA 
transferases or less frequently, phosphotransbutyrylase and butyrate kinase as 
final enzymes of the pathway (Figure 7) (Flint, Duncan, Scott, & Louis, 2007; 
Louis et al., 2014). Eubacterium rectale, Roseburia spp., Coprococcus catus, 
Anaerostipes spp., Eubacterium hallii and Faecalibacterium prausnitizii are 
bacterial species that produce butyrate via the CoA-transferase pathway. 
Coprococcus eutactus and Coprococcus comes produce butyrate via the 
butyrate kinase pathway. In addition to these two main pathways, butyrate can 
be generated from other metabolites, this is sometimes referred to as cross-
feeding. For instance, Eubacterium hallii and Anaerostipes caccae can convert 
acetate and lactate into butyrate (Pryde, Duncan, Hold, Stewart, & Flint, 2002).  
The production of butyrate is affected by several factors, including an 
individual’s difference in gut microbiota, intestinal pH, sources of DF, and other 
bacterial-derived metabolites and environmental factors (biotic therapy) (Flint et 
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al., 2015; Guilloteau et al., 2010; Pryde et al., 2002). Appropriate intestinal pH is 
pivotal to maintain butyrate-producing bacteria and butyrate levels in the colon. 
For example, an in vitro fermentation study found that the population of butyrate-
producing bacteria and the butyrate level was higher at pH 5.5, suggesting that 
lower intestinal pH helps to maintain a beneficial environment for butyrate-
producing bacteria (Walker, Duncan, Leitch, Child, & Flint, 2005). Although most 
fermentable DF play a role in SCFAs productions, resistant starches and fructo-
oligosaccharides are considered the most effective butyrogenic DF (Guilloteau et 
al., 2010; Topping & Clifton, 2001). Moreover, other metabolites such as acetate 
and lactate are critical in butyrate’s synthesis due to microbial community 
interaction and cross-feeding (Pryde et al., 2002).  
The approximate butyrate concentration in the human colon ranges from 
10 to 30 mM (total SCFAs concentration is 60-150 mM). The majority of the 
butyrate (95%) is rapidly absorbed into and utilized by colonic epithelial cells 
resulting in undetectable butyrate levels in portal blood (Louis et al., 2014; Pryde 
et al., 2002; Rémésy, Demigne, & Morand, 1992). Butyrate is mainly transported 
into colonocytes via monocarboxylate transport protein 1 (MCT1) (M Astbury & M 
Corfe, 2012). Once transported into the cell, butyrate undergoes mitochondrial β-
oxidation to produce acetyl-CoA, which then enters the TCA cycle and is used for 
ATP production (Hagland & Søreide, 2015). β-oxidation of butyrate is modulated 
by several enzymes including short-chain acyl-CoA dehydrogenase (SCAD), 
enoyl-CoA hydratase, and short-chain hydroxyacyl-CoA dehydrogenase 
(SCHAD) (M Astbury & M Corfe, 2012). Of these enzymes, SCAD plays a 
31 
 
significant role in butyrate metabolism; hence, SCAD deficiency increases 
butyrate excretion and decreases catabolism up to 60% (Bhala et al., 1995; M 
Astbury & M Corfe, 2012). In addition, the deletion and/or mutation of SCAD 
results in inefficient metabolism of butyrate as an energy source (Augenlicht et 
al., 1999). Donohoe et al. (2011) observed that colonocytes of germfree mice 
(lacking bacterial-derived butyrate production) have lower expression of key 
enzymes necessary for the TCA cycle (Donohoe et al., 2011). Interestingly, the 
addition of butyrate allows germfree mice colonocytes to recover their defects in 
mitochondrial respiration and inhibit their autophagy. Moreover, this rescue is 
due to butyrate’s role as an energy substrate for colonocytes rather than as an 
HDACi (Donohoe et al., 2011). Later it was reported that the proximal colon of 
germfree mice showed lower ATP levels when compared to other tissues 
(Donohoe, Wali, Brylawski, & Bultman, 2012). However, the addition of a 
butyrate-fortified diets partially rescued the slowed cell cycle and stimulated 
oxidative metabolism in germfree colonocytes, thus suggesting that butyrate was 
a major factor in these two processes (Donohoe, Wali, et al., 2012). This 
evidence also illustrates butyrate’s primary role as an energetic substrate for 
colonocytes. Butyrate is also a crucial substrate for lipogenesis through the 
mitochondrial β-oxidation pathway and eventual conversion to cytosolic acetyl-
CoA (Rémésy et al., 1992). Specifically, butyrate-derived acetyl-CoA in the 
mitochondria in combination with oxaloacetate (OAA) is used to generate citrate 
in the initial step of the TCA cycle. Citrate is then exported into the cytosol, where 
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it is broken back down into acetyl-CoA and OAA (Bultman, 2014b). The acetyl-
CoA provides the initial backbone used in lipogenesis.  
Another major function of butyrate is its role as an HDACi which regulates 
epigenetic modifications by increasing histone acetylation (Havenaar, 2011; 
Macfarlane & Macfarlane, 2012). HDACs inhibition relaxes the chromatin 
wrapped around histones, making DNA more accessible to transcription factors 
and eliciting a subsequent change in gene expression (Encarnacao, Abrantes, 
Pires, & Botelho, 2015). Butyrate has been deemed as the strongest HDACi 
among bacterial-derived SCFAs, which allows it to effectively reduce cell 
proliferation and regulate the expression of specific genes such as cyclin-
dependent kinase, p21 and pro-apoptotic proteins, BAX and Fas (Bultman, 
2014b; Davie, 2003). Most HDACs, except class III HDAC and class II HDAC 6 
and 10, are suppressed by butyrate (Davie, 2003). As an HDACi, butyrate also 
protects against intestinal inflammation via suppression of NF-γB activation, 
inhibition of interferon-γ production and/or signaling, and upregulation of PPAR-γ, 
suppression of oxidative stress via reduction of H2O2-induced DNA damage, 
enhanced antioxidant glutathione activity and increase catalase and glutathione-
S-transferase (Canani, Di Costanzo, & Leone, 2012; Hamer et al., 2008; Jacobs, 
Gaudier, Duynhoven, & Vaughan, 2009; Leonel & Alvarez-Leite, 2012; Scharlau 
et al., 2009). Butyrate can also exert beneficial effects in the intestinal barrier 
(Plöger et al., 2012). Due to the multiple effects of butyrate, it has received 
widespread attention as a general anti-CRC molecule. 
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Recent advances indicates that butyrate’s role in histone acetylation is 
more complicated than previously described (Bultman, 2014b; Donohoe, Curry, & 
Bultman, 2013). According to Donohoe et al. (2012), butyrate is involved in 
histone acetylation through two distinct mechanisms, ACL-dependent and/or 
ACL-independent, which relies on butyrate concentrations (Bultman, 2014b; 
Donohoe, Collins, et al., 2012). This dose-base mechanism is significant with 
regards to regulation of cell proliferation and/or apoptosis of colonocytes (Figure 
8) (Bultman, 2014b; Donohoe, Collins, et al., 2012; Donohoe et al., 2013). For 
example, an ACL-dependent mechanism is more likely to occur at relatively low 
doses of butyrate (0.5 mM) where butyrate undergoes mitochondrial β-oxidation, 
producing acetyl-CoA via ACL. Although cytosolic acetyl-CoA is utilized to 
synthesize lipids, nuclear acetyl-CoA serves as a cofactor for histone 
acetyltransferases (HATs) (Wellen et al., 2009). In the nucleus, butyrate modifies 
histone acetylation, accounting for 75% of gene expression, which is mostly 
related to cell proliferation (Donohoe, Collins, et al., 2012). In contrast, at high 
doses (5 mM), butyrate accumulates in the nucleus and mediates histone 
acetylation as a HDACi (ACL-independent mechanism). The accumulation of 
butyrate at high concentrations is due to the limited oxidative metabolic ability of 
these cells (1-2 mM) (Andriamihaja, Chaumontet, Tome, & Blachier, 2009). As an 
HDACi, butyrate accounts for 75% gene expression (such as FAS and WNT10B) 
which are associated with apoptosis (Donohoe, Collins, et al., 2012).  
Butyrate is believed to exist in a gradient of higher concentration in the 
upper side of the crypts and lower levels at the base of the crypts due to the 
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mucous flow (Donohoe, Collins, et al., 2012; Tan et al., 2014). According to the 
previous findings, the base of the crypts is composed of proliferative cells while 
the upper part of the crypts is filled with apoptotic cells for luminal exfoliation 
(Bultman, 2014b; Donohoe, Collins, et al., 2012; Yu, Wang, Wei, & Ni, 2012). 
The recent findings indicate that butyrate’s regulation of gene expression 
differences may be due to dose-dependent mechanisms (Donohoe, Collins, et 
al., 2012). Therefore, butyrate may maintain colonic epithelial cells homeostasis 
through these interesting mechanisms (ACL-dependent and/or ACL-
independent) that regulate gene expression (Figure 8) (Bultman, 2014b; 
Donohoe, Collins, et al., 2012). Overall, the relationship between the metabolic 
fate of butyrate (being oxidized and/or accumulated) and its functions (i.e. 
HDACi) may account for the inconsistent butyrate actions in normal versus 
cancerous colonocytes (Donohoe et al., 2013; Hague et al., 1997; Leonel & 
Alvarez-Leite, 2012). The next section (1.3.2. cancer cell metabolism -The 
Warburg effect) will cover the metabolic characteristics of cancerous cells that 
may influence butyrate’s metabolism and its functions. 
The ability of butyrate to regulate biological mechanisms also comes from 
interactions with G-protein-coupled receptors (GPCRs) that modulate signaling 
pathways (Louis et al., 2014). Butyrate can be a ligand for GPR41, GPR43, and 
GPR109A that are expressed along the entire GI tract (Guilloteau et al., 2010; 
Jacobs et al., 2009; Tan et al., 2014). GPR 43 and GPR 41 are primarily 
expressed in the intestinal endocrine L-cell, where it releases intestinal peptide 
YY (PYY) and glucagon-like peptide 1 (GLP-1) (Kasubuchi, Hasegawa, 
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Hiramatsu, Ichimura, & Kimura, 2015). PYY suppresses the appetite as an 
neuroendocrine factor and GLP-1 stimulates the pancreas to secrete insulin 
(Gropper & Smith, 2012; Stipanuk & Caudill, 2013). Tolhurst et al. (2012) 
observed that butyrate triggers GLP-1 secretion in mixed colonic cultures in vitro 
(Tolhurst et al., 2012). In addition, administration of tributyrin, a butyrate prodrug, 
improves insulin resistance in obese mice (Vinolo et al., 2012). By interacting 
with GPR109A, butyrate also attenuates colonic inflammation and anti-
inflammatory mechanisms via colonic immune cells (Kasubuchi et al., 2015). 
Thus, butyrate can enhance insulin sensitivity, mediate food intake and inhibit 
colonic inflammation as a ligand of GPCRs (Kasubuchi et al., 2015; Tan et al., 
2014).  
As an energy substrate, epigenetic regulator and GPCR ligand, butyrate 
can be involved in a variety of mechanisms related to colonic and host health 
(Figure 9). However, the most highlighted role of butyrate is as an HDACi, which 
is highly associated with its metabolic fate in colonocytes. Therefore, it is 
important to understand butyrate’s metabolic fate in colonocytes in order to 
identify its anti-cancer mechanisms against CRC. 
1.3.2. Cancer Cell Metabolism -The Warburg Effect  
Cancer cell metabolism is often described as involving the Warburg effect, 
which is characterized by rapid glucose utilization and lactate production (also 
known as aerobic glycolysis) (Warburg, 1956b). In aerobic glycolysis, most 
cancer cells rapidly metabolize glucose for ATP generation (~4 ATP/mol 
36 
 
glucose), rather than the more efficient pathway of oxidative phosphorylation 
(OXPHOS, ~36 ATP/mol glucose) (Cairns, Harris, & Mak, 2011; Vander Heiden, 
Cantley, & Thompson, 2009). In the 1950s, Otto Warburg hypothesized that 
mitochondrial dysfunction lead to this metabolic phenomenon in cancer cells; 
however, it has been demonstrated that most cancer cells maintain their normal 
OXPHOS ability (Garber, 2004; Rossignol et al., 2004; Warburg, 1956a). It has 
been suggested that the Warburg effect is the metabolic adaptation of the cancer 
cells in order to obtain abundant ATP production and biosynthetic advantages 
(Hsu & Sabatini, 2008; Kaelin Jr & Thompson, 2010).  
Cancer cells consume high levels of energy and proliferate rapidly, 
requiring sufficient amounts of ATP as well as ample cellular components such 
as nucleotides, fatty acids, membrane lipids, and proteins availability for rapid 
growth (Hsu & Sabatini, 2008). Although aerobic glycolysis is less efficient 
regarding ATP production, the abnormal glycolytic rate of cancer cells can 
counteract this low productive efficiency (Feron, 2009; Vander Heiden et al., 
2009). According to previous research, cells using aerobic glycolysis also have a 
high ratio of ATP/ADP and NADH/NAD exceeds the results from OXPHOS 
(DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008; Vander Heiden et al., 
2009). In addition, this fast glycolytic rate allows the cancer cells to obtain the 
required building blocks needed for their rapid cellular expansions (Jones & 
Thompson, 2009). The TCA cycle is known as a main bioenergetic center as well 
as biosynthetic hub for the cells by supplying diverse precursors for nucleotides, 
lipids and protein synthesis (DeBerardinis, Sayed, Ditsworth, & Thompson, 2008; 
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Jones & Thompson, 2009). As shown in figure 10, the high rate of aerobic 
glycolysis allows cancer cells to obtain biosynthetic intermediates via the TCA 
cycle (DeBerardinis, Sayed, et al., 2008; Feron, 2009; Jones & Thompson, 
2009). The pentose phosphate pathway generates ribose-5-phosphate for 
nucleotide synthesis, and NADPH (nicotinamide adenine dinucleotide phosphate, 
reduced) for nucleotides and fatty acids synthesis (Jones & Thompson, 2009; 
Vander Heiden et al., 2009). In addition, cytosolic citrate is cleaved by ATP-
citrate lyase (ACL) to supply acetyl-CoA, which is the lipogenic precursor for 
cholesterol and fatty acids synthesis and oxaloacetate (OAA) for non-essential 
amino acids (Feron, 2009; Hsu & Sabatini, 2008).  
The mechanisms that permit cancer cells to achieve this metabolic 
transformation are stimulated by altering signaling pathways; mutations in 
oncogenes and tumor-suppressor genes; and modifying expressions of enzymes 
that impact metabolic flux rate and activity (Bensinger & Christofk, 2012; Dang & 
Semenza, 1999; DeBerardinis, Sayed, et al., 2008; Kim & Dang, 2006; Ward & 
Thompson, 2012). These molecular and cellular alterations cause the cancer 
cells to preferably use aerobic glycolysis rather than OXPHOS, resulting in an 
efficient bioenergetic and biosynthetic system for rapid growth and proliferation 
(Table 5) (Bensinger & Christofk, 2012; Cairns et al., 2011; DeBerardinis, Lum, et 
al., 2008; DeBerardinis, Sayed, et al., 2008; Feron, 2009; Hsu & Sabatini, 2008; 
Ward & Thompson, 2012). The current understanding behind metabolic 
transformation of cancer cells allows more specific therapeutic approaches 
against cancer (Tennant, Durán, & Gottlieb, 2010). For example, dichloroacetate 
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(DCA), an inhibitor of pyruvate dehydrogenase kinase, ameliorates tumor growth 
in vivo and in vitro studies (Michelakis, Webster, & Mackey, 2008).  
Therefore, understanding the metabolic transformation of cancer cells may 
eventually lead to the development of therapies against CRC. In addition, an anti-
CRC therapy like butyrate may be effective, but further research is needed to 
understand its metabolism and functions in cancerous colonocytes. 
1.3.3. Butyrate Metabolism in Colorectal Cancer Cells 
As the preferred energy substrate, butyrate increases cell metabolism and 
proliferation of normal colonocytes. However, in cancerous colonocytes, butyrate 
inhibits cell proliferation and induces apoptosis. This opposing effect of butyrate 
on the proliferation in normal versus cancerous colonocytes is known as butyrate 
paradox (Bultman, 2014a; Leonel & Alvarez-Leite, 2012). Previous publications 
emphasized that the butyrate paradox may result from the differences in butyrate 
concentration and exposure time across the studies and the cell’s ability to 
oxidize butyrate (Hamer et al., 2008; Leonel & Alvarez-Leite, 2012).  
Since colonocytes metabolize butyrate as their primary energy source, 
metabolic transformation in cancerous colonocytes significantly changes 
butyrate’s metabolic fates (Hague et al., 1997). According to Donohoe et al. 
(2012), normal colonocytes metabolize butyrate through the mitochondrial 
oxidative pathway; however, cancerous colonocytes undergo high levels of 
glycolysis with a reduction in mitochondrial OXPHOS (the Warburg effect) 
(Figure 11) (Donohoe, Collins, et al., 2012; Donohoe et al., 2013). As a result, 
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butyrate accumulates in the nucleus and acts as an HDACi to control genes that 
inhibit cell proliferation and increase apoptosis (Donohoe et al., 2013). 
Interestingly, inhibition of the Warburg effect and addition of butyrate stimulates 
proliferation in a way that resembles normal colonocytes (Donohoe, Collins, et 
al., 2012). However, butyrate-stimulated proliferation was dependent upon low 
levels (0.5-1 mM), whereas butyrate reduces proliferation and increases 
apoptosis at high concentrations (2-5 mM) (Donohoe, Collins, et al., 2012). This 
was consistent with the previous observation that 1-2 mM is the oxidative 
capacity of these cells (Andriamihaja et al., 2009). Thus, at levels higher that 2 
mM, butyrate accumulates in the nucleus instead of being oxidized, and acts as a 
HDACi both in normal colonocytes and cancerous colonocytes (Donohoe et al., 
2013). These 0.5~5 mM concentration range in their studies is physiologically 
relevant because butyrate’s approximate concentration is ~30 mM in the lumen 
of colon (Donohoe et al., 2013; M Astbury & M Corfe, 2012). Overall, the 
metabolic fate of butyrate in colonocytes is significantly involved in its function as 
an energy source or HDACi. 
Previous studies observed altered gene expression of the metabolic 
enzymes relating to the mitochondrial functions and butyrate β-oxidation in CRC 
(K. Y. Fung, Cosgrove, Lockett, Head, & Topping, 2012; Kitahara et al., 2001). 
One study investigated the gene expression in CRC throughout progression and 
different stages; they found genes involved in metabolism, particulatly 
mitochondrial metabolism, are the most commonly altered (22%) (Birkenkamp-
Demtroder et al., 2002). They also found that lipid metabolism related genes are 
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mainly down-regulated, and expression of SCAD is significantly decreased in all 
stages of CRC (Birkenkamp-Demtroder et al., 2002). Since SCAD catalyzes the 
first step of butyrate oxidation, decreased SCAD may influence butyrate 
metabolism and subsequent change in butyrate roles (M Astbury & M Corfe, 
2012; van Maldegem et al., 2006).  
In summary, the dysfunction of mitochondrial β-oxidation system and 
reduced gene expression of related enzymes in CRC may change butyrate 
metabolism in the colonocytes. Since the metabolic fate of butyrate in 
colonocytes is highly related to its function, further understanding of butyrate 
metabolism in cancerous colonocytes is strongly suggested to understand its role 
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Non-digestible constituents making up the plant cell wall. 
FAO/WHO 
(1995)  
The edible plant or animal material not hydrolyzed by the endogenous 





The edible parts of plants or analogous carbohydrates that are resistant to 
digestion and absorption in the human small intestine with complete or 
partial fermentation in the large intestine. Dietary fiber includes 
polysaccharides, oligosaccharides, lignin and associated plant substances. 
Dietary fibers promote beneficial physiological effects including laxation, 




Dietary fiber consisting of non-digestible carbohydrates and lignin that are 
intrinsic and intact in plants. Functional fiber consisting of isolated, non-
digestible carbohydrates which have beneficial physiological effects in 




Defined dietary fiber as: carbohydrate polymers with a degree of 
polymerization not lower than three, which are neither digested nor 
absorbed in the small intestine. Dietary fiber consists of one or more of: 
edible carbohydrate polymers naturally occurring in the food as consumed; 
Carbohydrate polymers obtained from food raw material by physical, 
enzymatic, or chemical means; Synthetic carbohydrate polymers.  










Dietary fiber is carbohydrate polymers with 10 or more 
monomeric units, which are not hydrolyzed by endogenous 
enzymes in the small intestine of human beings and belong to 
following categories: Edible carbohydrate polymers naturally 
occurring in food as consumed; Carbohydrate polymers, 
which have been obtained from raw material in food by 
physical, enzymatic, or chemical means and which have been 
shown to have physiological effects of benefit to health by 
generally accepted scientific evidence to competent 
authorities; Synthetic carbohydrate polymers, which have 
been shown to have physiological effect of benefit to health by 
generally accepted scientific evidence to competent 
authorities.  
The definitions of dietary fibers from the different organizations are listed. 
FAO/WHO; Food and Agriculture Organization of United Nations and World 
Health Organization, AACC; American Association of Cereal Chemists, NAS; 
National Academy of Science, CAC; Codex Alimentarius Commission, 




Table 2 Dietary fiber in the diet 



































































Dietary fiber is listing based on the origin (natural- or artificial- occurring). Then, it 
is categorized depend on the source (plants, algal, animals and/or synthesized). 




Table 3 General classification of dietary fiber 
Physicochemical 
property 
Degree and dietary fiber 
Solubility High Low 
Pectin, β-glucan, Gums, 
Polydextrose, Inulin 
Wheat bran, cellulose, 
Some hemicellulose, Lignin 
Viscosity High Low 




Fermentability Well Poor- or partial 
Pectin, β-glucan, Gums, Inulin, 
Resistant starch, Non-starch 




Lignin, Cutin, Suberin, 
Waxes, Chitin, Chitosan, 
Collagen 
Dietary fiber is differentiated regarding their physicochemical properties including 




Table 4 Summary of epidemiological studies regarding on the 
consumptions of DF and CRC incidence 
Study Design Dietary 
fiber 
Conclusion Year 
Protective effects  










Fiber-rich diets provide the 
protective effects against CRC 
1990 




fibers Intake of fiber-rich foods is 
inversely associated with the risk of 
CRC 
1992 
Bingham et al. observational 
study 
(N=519,978) 
fibers DFs in foods was inversely related 
to large bowel cancer incidence 
2003 
Dahm et al. prospective 
case-control 
study (N=579) 
fibers Consumption of DFs has inverse 
association with CRC risk 
2010 
No and/or weak associated 
Fuchs et al. prospective 
study 
(N=88,757) 
fibers There is no supportive evidence on 
the protective effects of DFs to 
CRC incidence 
1999 







Consumption of fruits and 
vegetables dose not shown 






fibers Relatively low intake of DFs has 
weak association with CRC risk 
2012 
Changeable depending on variables 





No association between cereal fiber 
and CRC risk, but low consumption 
of fruits and vegetables have the 
greater risk of CRC 
2001 
Park et al. pooled analysis 
(prospective 
cohort studies) 
fibers In aged-adjusted cases, DFs 
inversely related to CRC. But, with 
accounting with other dietary risk 
factors, there is no association 
2005 












High intake DFs, particularly cereal 
fiber and whole grains has inverse 
association with CRC, whereas 
other fibers have weak association 
2011 
Based on their conclusions, epidemiological studies are divided into the three 
categories; protective effects, no and/or weak associated, and changeable 




Table 5 The molecular and cellular alterations in cancer cells that leads 
metabolic transformations 






PI3K/Akt  glucose transporter expression ↑ 
 glycolytic enzymes expression ↑ (e.g. 
hexokinase) 
 glucose-carbon flux into biosynthetic 
pathways ↑ (e.g. direct regulation of ACL 
activity) 
 lipogenic gene expression ↑ (e.g. 
SREBP-1, ACL, ACC and FAS) 
 β-oxidation and fatty acids degradation ↓ 
 activation of mTOR pathway 
mTOR  protein synthesis and cell growth ↑ 
Gene expression 
(activated or loss) 
Activation of 
HIFα 
 glucose transporter expression ↑ 
 aerobic glycolytic enzymes expression ↑ 
(e.g. PDK and LDH) 
 promotion of aerobic glycolysis & 
reduction of OXPHS  
 activation of PI3K/Akt pathway 
Activation of c-
Myc  
 glucose transporter expression ↑ 
 aerobic glycolytic enzymes expression ↑ 
(e.g. PDK and LDHA) 
 promotion of aerobic glycolysis & 
reduction of OXPHS  
Loss of p53  glycolysis ↑ 
 expression of enzymes related to 
OXPHS ↓ 





LDH  conversion of pyruvate into lactate ↑ 
PDK  inactivation (=phosphorylation) of PDH ↑ 
 import of pyruvate into the TCA cycle  ↓ 
ACL  conversion cytosolic citrate into acetyl-
CoA and OAA ↑ 
 fatty acids and lipid synthesis ↑ 
The altered molecular and cellular metabolism that leads cancer cells to attain high 
rates of aerobic glycolytic systems and efficient biosynthetic mechanisms. PI3K; 
phosphatidylinositol 3’ kinase, ACL; ATP-citrate lyase. mTOR; mammalian target of 
rapamycin, SREBP-1; sterol regulatory element-binding protein-1, ACC; acetyl-CoA 
carboxylase, FAS; fatty acid synthase, HIFα; hypoxia-inducible factor α, PDK; 
pyruvate dehydrogenase kinase, LDH(A); lactate dehydrogenase (A), OXPHS; 





Figure 1 Vogelgram of colorectal cancer 
Involvement of four main gene’s alteration (bolds) related to CRC development 
and subsequent signaling pathways from (in) activation of those genes are 
shown (▲: activated, ▼: inactivated). Consequent events that influence on cell 
proliferation and apoptosis resulting in formation of aberrant crypt foci, adenoma 
and carcinoma are described at the bottom (↑: increase, ↓: decrease). At the 
beginning of CRC development, inactivation of APC gene triggers the 
adenomatous process. Next, activation of K-Ras is required to promote the 
growth of adenoma. Mutations in SMAD 2/4 and TP53 give rise to tumor 
expansion and malignant transformation of CRC. APC denotes adenomatous 
polyposis coli, MAPK mitogen-activated protein kinases, TGF-β transforming 




Figure 2 Risk factors of colorectal cancer. 
The risk factors toward CRC are shown. It includes non-modifiable factors (age, 
gender, family history and individual history), modifiable factors (lifestyle-related 
and dietary factors) and semi-modifiable factor (metabolic diseases). The box 
with each risk factor has a summary of the facts that increase or decrease the 
susceptibility of CRC development. The Solid line and box represent a positive 
association with CRC and the dotted line and box represent a negative 






Figure 3 Dietary recommendations to prevent CRC development 
 
To reduce CRC risk, several dietary interventions can be suggested. Less intake 
of red and processed meat, saturated fat and animal fat decrease CRC 
development. More intake of dietary fiber, whole grains, and fruits and 
vegetables reduce CRC incidence. In addition to these dietary factors, moderate 
energy intake focusing on variety, nutrients density and amounts of diet can be 




Figure 4 The beneficial physiological effects of dietary fiber and its 
underlying mechanisms. 
Based on their physicochemical properties (▲: relatively high, ▼: relatively low), 
DF is responsible for a variety of physiological effects. These effects are mainly 
involved in the improvement of blood glucose and lipid metabolism, laxation, 
overall improvement of colonic status and reduced risk in CRC development (↑: 




Figure 5 The beneficial physiological influences from gut microbiota and its 
underlying mechanisms 
Gut microbiota supply various metabolites from DF fermentation. Those 
bacterial-derived metabolites, SCFAs and gases are involved in the maintenance 
of colonic health and homeostasis, and host energy metabolism. Also, they are 
related to CRC incidence through diverse physiological routines (↑: increase, ↓:  
decrease). DFs; dietary fibers, SCFAs; short-chain fatty acids, CRC; colorectal 





Figure 6 The influential factors on the composition of gut microbiota and 
its impacts on the maintenance of colonic health and CRC development. 
Several factors can impact on the maintenance and/or change of the gut 
microbiota composition in terms of diversity, number and their activity. The 
condition of the host (genetic, age, stress), diseases (IBDs, obesity, diabetes), 
diet (HFD and DFs), and environmental factors (antibiotic therapy) can alter the 
composition of gut microbiota. The transformation of gut microbiota is directly 
related to colonic homeostasis and their outcomes (bacterial-derived metabolites) 
in respect of the types and amounts. Interruption of microbial homeostasis can 
change the population of gut microbiota, and produce the potential carcinogenic 
molecules and toxic compounds leading to CRC incidence. Therefore, the 
balance of gut microbiota is important in maintaining gut microbiota’s 
homeostasis, colonic conditions, and host health. IBDs; inflammatory bowel 





Figure 7 The pathways of butyrate production and the related butyrate-
producing bacteria in the colon. 
In the human colon, several bacteria participate in butyrate production and two 
major pathways are utilized by them. According to enzymes that they utilize at 
the end of pathway, butyrate-producing bacteria can be categorized into either 
CoA-transferase pathway or butyrate kinase pathway. The overall butyrate 
biosynthesis pathway and the involved bacteria are shown. DHAP; 





Figure 8 Two distinct mechanisms of butyrate in the histone acetylation. 
 (A) Butyrate presents in a gradient through the crypts (upper ~ base) due to the 
mucosal flow. The gradient concentration of butyrate relates the butyrate 
mechanisms in histone acetylation. Near the lumen, colonocytes are exposed to 
high doses of butyrate (5mM). In here, butyrate increases cell apoptosis and 
decreases proliferation as HDAC inhibitor (ACL-independent mechanism) to 
exfoliate. Whereas, at the bottom of the crypts, butyrate concentration is 
relatively lower (0.5mM). At this locations, butyrate is metabolized via 
mitochondrial β-oxidation and produces acetyl-CoA. As cofactor (acetyl-CoA) for 
HATs, butyrate regulates histone acetylation leading to an increase in cell 
proliferation and decrease in cell apoptosis (ACL-dependent mechanism). It may 
associate with butyrate’s roles in the turnover of colonic epithelial cells to 
maintain colonic homeostasis. (B) The graph shown above is to explain 
butyrate’s two distinct mechanisms in histone acetylation depending on its 







Figure 9 The roles of butyrate in various mechanisms related to maintain 
colonic- and/or host health. 
As an energetic substrate, epigenetic regulator, and ligand, butyrate plays a role 
in many mechanisms to maintain colonic- and host health. Butyrate produces 
ATP for colonic epithelial cells and the host. It also acts on signaling and 
mechanisms to exert anti-inflammatory and anti-oxidative stress effect. In 
addition, butyrate is involved in body weight regulation through activation of 
GPCRs, and controls gene expressions as HDAC inhibitor to show anti-cancer 
effects. SCFAs; short chain fatty acids, ATP; adenosine triphosphate, GPCR; G-
protein-coupled receptor, HDACi; histone deacetylase inhibitor, ROS; reactive 




Figure 10 The metabolic transformation in cancer cells. 
 From the high glycolytic metabolism rate, cancer cells can get massive amounts 
of biosynthetic substrates to meet their rapid growth and cellular expansions. The 
pentose phosphate pathway generates the nucleotides (ribose-5-phosphate) for 
RNA and DNA synthesis, and NADPH for lipid synthesis. Cytosolic citrate divides 
into acetyl-CoA and oxaloacetate that are necessary for fatty acids and amino 
acids synthesis, respectively. G-6-P; glucose-6-phosphate, 6-G-gluconate; 6-
phosphogluconate, PEP; phosphoenolpyruvate, α-KG; α -ketoglutarate, OAA; 
oxaloacetate, TCA; tricarboxylic acid, AAs; amino acids, NADP; nicotinamide 
adenine dinucleotide phosphate, RNA; ribonucleic acid, DNA; deoxyribonucleic 
acid, LDHA; lactate dehydrogenase A, PDH; pyruvate dehydrogenase, ACL; 




Figure 11 The different metabolisms of butyrate and roles between normal 
colonocytes and cancerous colonocytes.  
Normal colonocytes utilize butyrate as a major energy source because butyrate 
enters mitochondrial β-oxidation and yields ATP. In contrast, because of the 
Warburg effect, cancerous colonocytes metabolize glucose over butyrate 
resulting in butyrate accumulation in the nucleus. In the nucleus, butyrate 
regulates genes that reduce proliferation and increases apoptosis as an HDAC 
inhibitor. ACL; ATP-citrate lyase, HATs; histone acetyltransferase, HDAC; 






CELLULAR METABOLISM AND DOSE REVEAL CARNITINE-
DEPENDENT AND -INDEPENDENT MECHANISMS OF 




A version of this chapter was originally published by Anna Han, Natalie 
Bennett, Amber MacDonald, Megan Johnstone, Jay Whelan, and Dallas R. 
Donohoe entitled “Cellular Metabolism and Dose Reveal Carnitine -Dependent 
and -Independent Mechanisms of Butyrate Oxidation in Colorectal Cancer Cells” 




Dietary fiber has been suggested to suppress colorectal cancer 
development, although the mechanisms contributing to this beneficial effect 
remain elusive. Butyrate, a fermentation product of fiber, has been shown to 
have anti-proliferative and pro-apoptotic effects on colorectal cancer cells. The 
metabolic fate of butyrate in the cell is important in determining whether, it acts 
as an HDAC inhibitor or is consumed as a short-chain fatty acid. Non-cancerous 
colonocytes utilize butyrate as the primary energy source whereas cancerous 
colonocytes increase glucose utilization through the Warburg effect. In this study, 
we show that butyrate oxidation is decreased in cancerous colonocytes 
compared to non-cancerous colonocytes. We demonstrated that colorectal 
cancer cells utilize both a carnitine-dependent and carnitine-independent 
mechanism that contributes to butyrate oxidation. The carnitine-dependent 
mechanism is contingent on butyrate concentration. Knockdown of CPT1A in 
colorectal cancer cells abolishes butyrate oxidation. In terms of selectivity, the 
carnitine-dependent mechanism only regulated butyrate oxidation, as acetate 
and propionate oxidation were carnitine-independent. Carnitine decreased the 
action of butyrate as an HDAC inhibitor and suppressed induction of H3 
acetylation by butyrate in colorectal cancer cells. Thus, diminished oxidation of 
butyrate is associated with decreased HDAC inhibition and histone acetylation. In 
relation to the mechanism, we find that dichloroacetate, which decrease 
phosphorylation of pyruvate dehydrogenase, increased butyrate oxidation and 
that this effect was carnitine-dependent. In conclusion, these data suggest that 
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colorectal cancer cells decrease butyrate oxidation through inhibition of pyruvate 
dehydrogenase, which is carnitine-dependent, and provide insight into why 
butyrate shows selective effects toward colorectal cancer cells. 
 
2.2 Introduction 
Diet is one of the risk factors associated with colorectal cancer 
susceptibility and dietary modifications have been proposed to lower colorectal 
cancer incidence and mortality (Bruce, Wolever, & Giacca, 2000; Ryan-
Harshman & Aldoori, 2007; Safari, Shariff, Kandiah, Rashidkhani, & Fereidooni, 
2013; Vargas & Thompson, 2012; Vargas et al., 2012; Willett, 2001). Several 
studies have shown that consumption of a high-fiber diet is associated with a 
reduction in colorectal cancer incidence and development (Bingham et al., 2003; 
Giovannucci, Stampfer, Colditz, Rimm, & Willett, 1992; Reddy, 1999; Schatzkin 
et al., 2007). In contrast, several other human epidemiological studies have failed 
to demonstrate a beneficial effect toward preventing colorectal cancer (Fuchs et 
al., 1999; Lanza et al., 2007; Mai et al., 2003). Thus, the role of dietary fiber in 
colorectal cancer prevention remains unclear and unresolved. The major 
metabolites derived from fiber include acetate, propionate, and butyrate. Of these 
metabolites, butyrate has been proposed to be a primary candidate in fiber’s 
suppressive effects toward colorectal cancer (Louis, Hold, & Flint, 2014; 
Wollowski, Rechkemmer, & Pool-Zobel, 2001). Butyrate is a short-chain fatty 
acid, produced in the colon by bacteria through fermentation of fiber, and is the 
preferred energetic substrate of the colonocytes (Donohoe et al., 2011; Flint, 
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Scott, Duncan, Louis, & Forano, 2012; WE Roediger, 1980). In addition, to 
butyrate’s role as an energetic substrate in colonocytes, butyrate inhibits cell 
growth, promotes cellular differentiation, and induces apoptosis in cancer cells in 
vitro at physiologically relevant doses (Archer, Meng, Shei, & Hodin, 1998; 
Chopin, Toillon, Jouy, & Bourhis, 2002; Velcich et al., 1995).  
Several previous studies have demonstrated that, the ability of butyrate to 
inhibit cell proliferation and induce apoptosis is directly associated with its 
metabolic fate (Andriamihaja, Chaumontet, Tome, & Blachier, 2009; Donohoe et 
al., 2012; Leschelle, Delpal, Goubern, Blottiere, & Blachier, 2000). Specifically, in 
colorectal cancer cells, increased glycolysis or the Warburg effect regulated the 
intracellular butyrate level, which was associated with butyrate inducing pro-
apoptotic genes through inhibition of histone deacetylases (HDACs; (Donohoe et 
al., 2012)). As an alternative to inhibiting HDACs, butyrate was oxidized 
completely through the Krebs cycle (to CO2) or butyrate directly gave rise to 
cytosolic acetyl-CoA (through citrate originating from the mitochondria). Cytosolic 
acetyl-CoA then donated acetyl groups to histone acetyltransferase (HATs) to 
regulate gene expression or it was used for de novo lipogenesis (Andriamihaja et 
al., 2009; Donohoe et al., 2012; Leschelle et al., 2000; Wellen et al., 2009). Thus, 
to understand butyrate’s inhibitory and selective effects toward colorectal cancer, 
it is essential to characterize the mechanisms that regulated butyrate oxidation.  
Carnitine and the carnitine palmitoyltransferase (CPT) system regulate 
fatty acid transport into the mitochondria. The CPT system, which utilizes 
carnitine palmitoyltransferase 1 (CPT1), carnitine acyltransferase, and carnitine 
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palmitoyltransferase 2 (CPT2), transports fatty acids across the outer and inner 
mitochondrial membranes into the matrix, and has been long known to have 
selectivity toward transporting long-chain fatty acid (Fritz, 1961). In the first 
reaction, carnitine palmitoyltransferase 1 (CPT1), uses carnitine for its transport 
mechanism as it converts the fatty acyl-CoA into the fatty acyl-carnitine ester. 
The fatty acyl-carnitine, is then shuttled through the CPT system/transporter into 
the mitochondrial matrix. In the final step, CPT2 converts the fatty acyl-carnitine 
back into the original fatty acyl-CoA, which is released in conjunction with 
carnitine into the matrix. This transport process is considered the major rate-
controlling step in fatty acid oxidation (Ceccarelli, Chomienne, Gubler, & Arduini, 
2011). The uptake of butyrate and other short-chain fatty acids (SCFAs) into the 
mitochondria has been shown not to require carnitine or the CPT system 
(Ceccarelli et al., 2011; Fritz, 1959, 1961).  However, it is important to recognize 
that many of these earlier studies that characterized fatty acid oxidation utilized 
lower SCFA concentrations (in the micromollar range), and cell-types, such as 
heart and liver, where SCFAs are not the primary energy source under 
physiological conditions. Thus, in the case of butyrate oxidation in the 
colonocytes, where colonic butyrate level reach millimolar concentrations, and 
butyrate serves as the preferential energetic substrate by the colonocytes, it is 
unknown as to whether carnitine and the CPT system, impact the oxidation of 
butyrate.  
In the study, experiments were performed to distinguish butyrate oxidation 
in the cancerous and non-cancerous colonocytes, while also further 
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characterizing the mechanisms that impact oxidation of butyrate in the cancerous 
colonocytes, and thus influence butyrate’s action as an HDAC inhibitor. 
Cancerous colonocytes showed diminished butyrate oxidation compared to non-
cancerous colonocytes. This result coincided with lower intracellular carnitine 
levels and decreased levels of organic cation/carnitine transporter 2 (OCTN2), a 
major carnitine transporter, in the cancerous colonocytes compared to non-
cancerous colonocytes. As a consequence, the role of carnitine in regulating 
butyrate oxidation in the cancerous colonocytes was interrogated further. Toward 
this end, butyrate oxidation was found to be both carnitine-dependent and 
carnitine-independent in the cancerous colonocytes. Furthermore, the carnitine-
dependent regulation of butyrate oxidation was mediated through the 
phosphorylation of pyruvate dehydrogenase, which is a major contributor to the 
Warburg effect (Fan et al., 2014; Hitosugi et al., 2011). This study provides an 
initial framework into understanding how shifts in cellular mechanism alter the 
fate of microbial-derived butyrate and determine its selective effects toward the 
colorectal cancer cell. 
 
2.3 Materials and Methods 
2.3.1. Cell culture and transfections 
HCT116 cells (ATCC, CCL-247) were grown in DMEM formulated with 
25mM glucose and 10% FBS. FHC cells (ATCC, CRL-1831) were grown in 
DMEM:F12 medium with 20% FBS. RNAi transfection in HCT116 cells was 
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performed as described (Donohoe et al., 2012), and siRNA pools for human 
Cpt1a (Dharmacon, L-009749-00), and siMock non-targeting control 
(Dharmacon, D-001810-01-05) were used at a 20nM final concentration. The 
optimized time for each siRNA transfection was confirmed with Western blotting.  
2.3.2. Flux experiment  
XF24 Analyzer (Seahorse Bioscience) was used to measure % change in 
the oxygen consumption rates (% OCR) in HCT 116 and FHC cells. Experiments 
were conducted following manufacturer guidelines. Cells (FHC and HCT116 
cells) split and seeded (at an identical cell number per well) into XF24 cell culture 
microplates (Seahorse Bioscience, 100777-004). Before running seahorse, cell 
plates are incubated with 1X KHB (2.5mM glucose, with or without 50μM 
carnitine) in non-CO2 incubator at 37℃ for 1h. All Seahorse experiments were 
run with identical condition (unless otherwise noted). Briefly, KHB media or short 
chain fatty acids (SCFAs) including sodium acetate, propionate or butyrate 
(Sigma P1880, S8750 and B5887) at 1 and/or 5mM final concentration were 
injected and the change in OCR was measured from baseline (%OCR). Next, 2-
deoxyglucose (Sigma, D8375) was injected and %OCR was measured again. 
Finally, 10% sodium azide was injected to block Complex Ⅳ and mitochondrial 
respiration. Azide was used as a positive control to show that mitochondrial 
respiration is responding as expected and our compounds have an effect on 
mitochondrial function. In all cases, azide decreased OCR to at or below baseline 
respiration. As we were initially developing the methodology to measure butyrate 
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oxidation with the Seahorse we did not use azide. When testing other cell lines 
(non-colonocyte) we found that they showed no response butyrate. However, 
they did response to azide (OCR dropped), thus suggesting that the lack of 
response to butyrate was real, and not an artifact of the Seahorse technology. In 
some situations, additional chemical compounds were injected: etomoxir (Tocris 
Bioscience, Minneapolis, MN, 4539), palmitate/or BSA from XF Palmitate-BSA 
FAO substrate kit (Seahorse Bioscience, #102720-100), and 5mM DCA (Sigma, 
347795).  
2.3.3. Western blotting 
Proteins from FHC and HCT116 cells were extracted with RIPA buffer 
(Cell Signaling, #9806), 1mM PMSF (Cell Signaling, #8553) and phosphatase 
inhibitor cocktail (Cell Signaling, #5872). Protein concentrations were measured 
by Bradford assay. Gel electrophoresis and transfer were conducted using 
standard protocol for Western blot. Antibodies that were used included pan-
acetylated-histone H3 (Active Motif, Cat#39139), total Histone H3 (Active Motif, 
Cat#39736), MCT1-c terminal (Abcam, Cat# ab179832), OCNT2 (Abcam, Cat# 
ab79964), CPT1A (Cell Signaling, Cat# 122525), phospho-PDH E1- α (S293) 
(Abcam, Cat# ab92696), PDH E1- α (Abcam, Cat# ab110330), and β-actin 
(Sigma, Cat# A1978). Chemiluminescence or fluorescent detection was 
performed with the Odyssey Fc and bands were quantified with Image Studio 




2.3.4. Carnitine assay 
Carnitine levels in FHC and HCT116 cells were measured with a carnitine 
assay kit (Biovision, K642-100). Conditions were kept identical to the Seahorse 
experiments. The assay was performed as described the protocol from the 
manufacturer. Cells were deproteinized immediately before the assay with a PCA 
deproteinization kit (Biovision, K808-200). The carnitine contents in cells were 
normalized to protein amounts.  
2.3.5. Statistical analysis 
For biochemical assays, Seahorse Experiments, and Western blots, the 
differences between experimental groups were determined by ANOVA followed 
by a Turkey post-hoc test. All data are expressed as mean ± SE.  
 
2.4 Results 
2.4.1. Diminished butyrate oxidation in colorectal cancer cells 
To test whether butyrate oxidation is altered in colorectal cancer cells 
compared to non-cancerous colonocytes, we first sought to develop methodology 
that would allow us to analyze butyrate oxidation over time, and to probe the 
mechanisms that regulated the process in more detail. Therefore, we utilized the 
Seahorse XF24 Analyzer to measure changes in the oxygen consumption rate 
(OCR) in cultured cells. In all of our Seahorse experiments, the assay is run in 
KHB media, were the only exogenous energetic substrate is glucose (2.5mM). 
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Thus, initial OCR measurements represent glucose oxidation. Injection of 
butyrate results in both butyrate and glucose contributing to OCR. To block 
glucose oxidation, and thereby leave butyrate as the sole exogenous substrate 
(butyrate oxidation), we decided to use 2-deoxyglucose (2DG), which is a 
competitive inhibitor of glucose and abolishes glucose oxidation (Figure 12A). 
We first tested this strategy utilizing HCT116 colorectal cancer cells. The % 
change in the OCR was measured as cells were treated with increasing 
concentrations of butyrate (0.5, 1.0, 2.0, and 5.0mM). Although the top three 
doses were elevated over 0.5mM, there was no distinct dose-response 
relationship. However, upon injection of 2DG (5mM) a dose-response could 
clearly be identified, presumably as butyrate as the only exogenous substrate 
available (Figure 12B). We then tested whether butyrate oxidation was different 
between non-cancerous Fetal Human Colonocytes (FHC) and cancerous 
HCT116 cells utilizing the same strategy. The % change in the oxygen 
consumption rate was much greater in FHC compared to HCT116 cells, 
suggesting that in general FHC have greater response to butyrate (Figure 12C). 
Moreover, after addition of 2DG, the butyrate oxidation was much greater in FHC 
compared to cancerous HCT116 cells (Figure 12D). This provided evidence that 
butyrate oxidation is suppressed in cancerous colonocytes compared to non-
cancerous colonocytes.  
Butyrate, uptake into the cell is accomplished through the 
monocarboxylate transporter І (MCT І). We next tested whether the cancerous 
cell line (HCT116) had diminished transport of butyrate compared to the non-
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cancerous cell line (FHC). However, when analyzing MCT І levels in the two cell 
lines, we actually find that MCT І expression was higher in HCT116 cells 
compared FHC. This suggests that butyrate uptake is not suppressed in HCT116 
cells (Figure 12E).  
2.4.2. Butyrate oxidation is regulated by carnitine-dependent and -
independent mechanism 
Transport of SCFAs into the mitochondria is recognized to be independent 
of carnitine palmitoyltransferase І (CPT І) (Ceccarelli et al., 2011; Fritz, 1961). 
However, butyrate oxdiation has been shown to be elevated throughcarnitine 
supplementation (Fritz, Kaplan, & Yue, 1962; Hird & Weidemann, 1966).These 
conflicting results are likely due to differences in cell-type and SCFA 
concentrations used in the studies. Nevertheless, we sought to determine 
whether carnitine and CPT impacts butyrate oxidation in our system. First, we 
measured intracellular carnitine levels in non-cancerous FHC and cancerous 
HCT116 cells. With assay conditions kept identical to when we measured 
butyrate oxidation, we found that the intracellular carnitine level was over 12 
times higher in FHC compared to HCT116 cells. (303 vs. 24μmols/g of protein) 
(Figure 13A). Next, we analyzed whether OCTN2, which is the major carnitine 
transporter (Ohashi et al., 2001; Seth, Wu, Huang, Leibach, & Ganapathy, 1999; 
Wu et al., 1999), is expressed differently in the FHC and HCT116 cells. The 
expression of OCTN2 was found to be elevated in FHC compared to HCT116 
cells (Figure 13B). To probe the role of carnitine in the oxidtaion of butyrate, we 
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performed the assay with KHB media containing carnitine and compared it to 
KHB media void of cartnitine. If butyrate oxdiation was carnitine-independent 
then we postulated that oxidation should not be affected by absence of carnitine. 
However, this was not the case, as the addition of 50μM carnitine to KHB media, 
the % change in oxygen consumpation rate following HCT116 cells treated with 
5mM butyrate was higher than KHB media without carnitine (Figure 13C). This 
was especially evident after 2DG injection as the butyrate oxidation showed both 
a carnitine-independent (even without carnitine, butyrate significantly increased 
the %OCR) and carnitine-dependent responses (Figure 13D). To test whether 
butyrate oxidation was carnitine-dependent at lower doses, we treated HCT116 
cells with 1mM butyrate in the presence or absence of 50μM carnitine. At this 
lower doses, 1mM HCT116 cells did not exhibit a carnitine-dependent response 
(Figure 13E). Thus, butyrate oxidation was not significantly impacted by carnitine 
(Figure 13F). These data reveal a carnitine-dependent mechanism that functions 
at higher butyrate doses to regulate oxidation in the cell. 
2.4.3. Carnitine-dependent mechanism is selective for butyrate oxidation 
To gain further insight into the impact of carnitine on butyrate oxidation in 
cancerous colonocytes, we tested increasing concentrations of carnitine (6, 12.5, 
25, and 50μM) with a fixed butyrate dose (5mM). As carnitine concentrations 
increased, so did the % change in the oxygen consumption rate after butyrate 
treatment (Figure 14A). This dose-response was especially apparent after 2DG 
treatment to block glucose oxidation, as butyrate oxidation was highest at 50μM 
87 
 
(Figure 14B). We next sought to determine whether this carnitine-dependent 
mechanism was prevalent for oxidation of other SCFAs. Thus, the major 
objective of this experiment was to test how carnitine impacted the oxidation of 
SCFAs, not how the oxidation of the SCFA differed from the each other. Using a 
set SCFA concentration of 5mM, we found that treatment of colorectal cancer 
cells (HCT116) with acetate or propionate failed to show the same carnitine-
dependent response as butyrate (Figure 14C). Moreover, only butyrate oxidation 
was significantly affected by carnitine (Figure 14D). This suggests that the 
carnitine-dependent oxidation is selective for butyrate in thses colorectal cancer 
cells.  
2.4.4. CPT1A-dependent oxidation of butyrate 
Carnitine regulates fatty acid oxidation through carnitine 
palmitoyltransferase (CPT), which transfers carnitine onto the fatty acid in 
exchange for coenzyme A (CoA). We reasoned that since butyrate oxidation 
was, in part, carnitine-dependent, at higher doses, then inhibiting or knocking 
down CPT1A (the major isoform in colonocytes) would have a similar outcome as 
taking away carnitine, where the oxidation of butyrate would be diminished. To 
test this idea, we decided to inhibit CPT1A with the pharmacological agent 
etomoxir, and transiently knockdown CPT1A with RNA interference. In the first 
set of experiments, we treated HCT116 cells with etomoxir (ETO) after the 2DG 
injection (so butyrate is the only available exogenous substrate), and found that 
the % change in the oxygen consumption rate decreased (Figure 15A). Thus, 
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butyrate oxidation was significantly diminished by the CPT1 inhibitor etomoxir 
(Figure 15B). To further confirm CPT1 involvement and selectively target CPT1A, 
we performed a time course knockdown of CPT1A in HCT116 cells. The time 
course was meant to determine the maximal knockdown of CPT1A, and set the 
conditions for the Seahorse assay. At 72hr, we observed maximal knockdown of 
CPT1A protein (Figure 15C). To confirm fatty acid oxidation was decreased, we 
conducted a series of experiments to test if palmitate oxidation was lower in cells 
where CPT1A was knockdown. This was indeed the cases, as knockdown 
CPT1A, completely abolished palmitate oxidation (Figure 15D). This result 
showed us that knockdown of CPT1A was having a functional consequence on 
fatty acid oxidation. We next tested whether butyrate oxidation was altered by 
CPT1A knockdown in HCT116 cells. CPT1A knockdown diminished the change 
in % oxygen consumption rate after butyrate injection (Figure 15E). CPT1A 
knockdown completely blocked butyrate oxidation in HCT116 cells (Figure 15F). 
These data point at role of CPT1A in regulating butyrate oxidation in the 
colonocytes. This is consistent with CPT1A having diminished expression in 
colorectal cancerous cells (HCT116) compared to non-cancerous colonocytes 
(FHC) (Figure 19).  
2.4.5. Lower butyrate oxidation results in elevated HDAC inhibition and H3 
acetylation 
As a result of diminished butyrate oxidation from lack of carnitine, we 
hypothesized that suppressed butyrate oxidation, would increase butyrate 
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concentration, and that would increase HDAC inhibition and histone acetylation. 
We discovered that HDAC activity was diminished in cells treated with 5mM 
butyrate whole media lacked carnitine (Figure 16A), thereby suggesting 
enhanced inhibition of HDACs at this concentration of butyrate. Absence of 
carnitine had no effect on HDAC activity for HCT116 cells treated with 1mM 
butyrate. If inhibition of HDACs was indeed enhanced then histone acetylation 
should be elevated. This was the case, as we demonstrated that HCT116 cells 
treated with butyrate without carnitine had greater H3 acetylation (H3ac) than 
cells treated with equal concentration of butyrate with carnitine (Figure 16B and 
C).   
2.4.6. Phospho-pyruvate dehydrogenase lowers oxidative metabolism and 
butyrate oxidation 
As cancer cells begin to increase glucose uptake and utilization through 
the Warburg effect, the pyruvate dehydrogenase complex (PDH) becomes 
inactive through phosphorylation of Ser 239 on the E1 subunit. We constructed a 
model based on targeting phospho-pyruvate dehydrogenase as a central player 
in mediating the diminised oxidation of butyrate in the colorectal cacner cells 
(Figure 17A). In this simplified model, pyruvate is shunted toward lactate as PDH 
becomes inactive through phosphorylation. The net result is lowered glucose 
oxidation (per molecule of glucose taken up), and an overall decrease in 
mitochondrial oxidation, including butyrate oxidation. In addition, elevated 
glucose utilization, and glycolysis, suppres OCTN2 expression (this results in 
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decreased carnitine uptake and concentration in cell), and lower butyrate 
oxdiation through the carnitine- dependent mechanism. To test this model, we 
used the compound dichloroacetate (DCA) to inhibit pyruvate dehydrogenase 
kinase and decrease phosphorylation of PDH (increase in activity). Therefore, 
treatment of colorectal cancer cells with DCA should increase butyrate oxidtion 
through this mechanism. DCA behaved as expected in our cells, as DCA 
inhibited phosphorylation of PDH (Ser 293) (Figure 17B). We next tested the 
effects of DCA on glucose and butyrate oxidation. Consistent with the model, 
initial injection of DCA (before butyrate oxidation), increased the % change in the 
oxygen consumpation rate, demonstrating that DCA elevated oxidative 
metabolism of glucose (Figure 17C), and butyrate oxidation (Figure 17D).  
2.4.7. Link between phospho-pyruvate dehydrogenase and carnitine 
To test whether there is a relationshipe between suppressed butyrate 
oxidation from phospho-PDH and carnitine, we sought to find out if the elevated 
butyrate oxdiation observed after DCA treatment was dependent in any way on 
carnitine. We first tested whether DCA had a significant impact on OCNT2 and/or 
CPT1A expression in cancerous HCT116 cells undergoing the Warburg effect. 
DCA elevated OCTN2 and CPT1A epxression (Figure 18A) in HCT116 cells. We 
then repeated the DCA experiemtns with and without carnitine, and analyzed 
butyrate oxidation with the Seahorse XF24 analyzer. Removing carnitine fully 
attenuated the butyrate oxidation response due to DCA treatment (Figure 18B). 
DCA and carnitine were required for maximal response (Figure 18C). Taken 
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together, these data point toward the phostphorlyation (and thus, inhibition) of 
PDH as a key event in suppressing butyrate oxidation in the colorectal cancer 
cell. This alos demonstrates that phosphorylation of PDH targets the carnitine-
dependent oxidation of butyraet through regulation of carnitine uptake and 
expression of CPT1A.  
 
2.5 Discussion 
The colonocytes is unique because butyrate serves the role of being the 
preferred energetic substrate (WE Roediger, 1980). It is also recognized that, 
cancerous colonocytes shift their metabolism toward increased glucose uptake 
and utilization as suggested by FDG uptake in Positron Emission Tomography – 
Computed Tomography (PET-CT) scans (de Geus-Oei et al., 2006; Delbeke & 
Martin, 2011; Kawada et al., 2015; van Kouwen et al., 2006). The change in 
cellular metabolism toward glucose utilization and the Warburg effect alters 
butyrate metabolism in the cell (Andriamihaja et al., 2009; Donohoe et al., 2012; 
Leschelle et al., 2000). As a result, butyrate levels in the cells are affected, as it 
inhibition of histone deacetylase (HDACs) by butyrate (Donohoe et al., 2012; 
Donohoe et al., 2014; Leschelle et al., 2000). In this regard, suppression of cell 
proliferation and induction of apoptosis in colorectal cancer cells by butyrate has 
been associated with inhibition of HDACs (Archer et al., 1998; Chopin et al., 
2002; Velcich et al., 1995). Therefore, it is essential to characterize the oxidation 
of butyrate in the cancer cell to understand the impact of butyrate as an HDAC 
inhibitor. If cancer cells are predisposed to accumulate butyrate compared to 
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normal colonocytes under the proper conditions, this could help explain why 
cancer cells are sensitive to fiber diets.  
In the work presented here, we define a diminished oxidation of butyrate in 
cancerous colonocytes and interrogate mechanism(s) that include carnitine and 
pyruvate dehydrogenase. We also demonstrate that with lower butyrate 
oxidation, HDAC inhibition and histone H3 acetylation increase in colorectal 
cancer cells.  
Previous studies have defined a role for carnitine in the oxidation of long-
chain fatty acids, and short-chain fatty acid oxidation is mainly accepted to be 
carnitine-independent (Ceccarelli et al., 2011; Fritz, 1959, 1961). In contrast, we 
find butyrate oxidation to be partially carnitine-dependent in cancerous 
colonocytes. This difference can be attributed to doses or concentrations of 
butyrate use, where butyrate concentrations were in the micromollar range. In 
our case, we used 5mM butyrate, which is a physiologically relevant 
concentration in the colon. Toward this end, we demonstrate at 1mM there is no 
carnitine-dependent mechanism involved in butyrate oxidation. This is consistent 
with the carnitine-dependent mechanism only functioning at higher butyrate 
doses, and this mechanism only being physiologically relevant to the colon. De 
Preter et al. (2011) fount that carnitine did not enhance the oxidation of 1mM 14C-
butyrate to 14CO2 in colonic biopsies from normal and ulcerative colitis patients 
(De Preter et al., 2011). A previous publication found that carnitine elevated 
butyrate oxidation in an ADP-dependent fashion (Hird & Weidemann, 1966).  
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The fact that carnitine levels were lower in HCT116 cells compared to 
FHC cells suggest that carnitine may be an important determinant in lowered 
butyrate oxidation observed in HCT116 cells. Thus, in addition to diminished 
butyrate-producing bacteria and butyrate levels that has been observed in 
colorectal cancer patient (Balamurugan, Rajendiran, George, Samuel, & 
Ramakrishna, 2008; Wang et al., 2012), butyrate oxidation may be decreased 
due to a reduction in carnitine in the colorectal cancer cell. We find that OCTN2, 
the major carnitine transporter, is higher in FHC compared to HCT116 colorectal 
cancer cells. This is consistent with a previous report that highlights a 
downregulation in OCTN2 in cancer cells, in general (Scalise et al., 2012). The 
mechanism causes the diminished carnitine level and decreased OCTN2 in 
cancer cells is unknown; however, it is interesting to consider increased 
glycolysis and diminished oxidative metabolism as a plausible starting point. 
Dichloroacetate (DCA) is a compound that has been used to decrease the 
phosphorylation of pyruvate dehydrogenase, and therefore, increase oxidative 
metabolism (Izquierdo-Garcia et al., 2015; Whitehouse, Cooper, & Randle, 
1974). We found that DCA could exert this effect on HCT116 cells, where 
phosphorylation of PDH was diminished by 10-fold in DCA treated cells. 
Moreover, HCT116 colorectal cells treated with DCA displayed elevated butyrate 
oxidation, which is consistent with phospho-PDH playing a role in the diminished 
butyrate oxidation observed in the colorectal cell. In a previous paper, Roediger 
and Nance (1990) reported that addition of DCA had no effect on conversion of 
14C-butyrate to 14CO2 (WEW Roediger & Nance, 1990). This suggests that the 
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increased butyrate oxidation caused by DCA, was specific for the cancer cell, 
where PDH was inactivated through phosphorylation. The selective effects of 
butyrate on colorectal cancer cells as opposed to non-cancerous cells may be 
the result of altered cellular metabolism with inactivation of PDH at the center of 
the cause through diminishment of butyrate oxidation.  
To date, there have been no human studies testing the effect of carnitine 
supplementation on colorectal cancer. However, dietary sources high in carnitine, 
such as red meat, have been associated with an increased risk for the 
development of colorectal cancer. Our data might suggest that consumption of 
red meat (high in carnitine) would increase the oxidation of butyrate and 
subsequently diminish HDAC inhibition. As a results of increase butyrate 
oxidation, butyrate’s protective actions toward colorectal cancer would be 
diminished. In addition, carnitine supplementation in humans has been shown to 
increase trimethylamine-N-oxide(TMAO) in a microbiota-dependent manner 
(Koeth et al., 2013). Elevated blood/plasma TMAO has been suggested to be a 
causal factor in colorectal cancer (Bae et al., 2014; Xu, Wang, & Li, 2015). Thus, 
carnitine supplementation may have tumor-promoting effects in humans that are 
fiber-or butyrate-dependent (carnitine’s role in regulating butyrate oxidation) and 
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Figure 12 Butyrate oxidation in non-cancerous and cancerous colonocytes. 
(A) Diagram showing experimental strategy that will be used to measure butyrate 
oxidation in cells over time with XF24 Analyzer. (B) Percent change in oxygen 
consumption rate (OCR) relative to baseline for 0.5, 1.0, 2.0, and 5.0mM butyrate 
in HCT116 cells. Total contribution of butyrate toward OCR (%) is observed after 
injection of 2-deoxyglucose (2DG). (C) Percentage change in OCR relative to 
baseline was determined in HCT116 and FHC cells with or without butyrate 
injected into the wells (final concentration of butyrate is 5mM). 2DG was then 
injected into wells and butyrate oxidation was analyzed. (D) Area under the curve 
analysis from OCR measurements taken after 2DG injection, but before azide 
injection (80-128min). These measurements represent the butyrate oxidation 
(arbitrary units), as butyrate is the only exogenous oxidative substrate available. 
(E) Representative western blot of MCT1 from FHC and HCT116 cells with β- as 
loading control. The glucose concentration in the in the fatty acid oxidation media 
for panels B and C was kept constant at 2.5mM. Data points represent the 
average OCR (%) over 3-5 replicates per experimental condition. Error bars are 




Figure 12 continued   
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Figure 13 Butyrate oxidation is carnitine -dependent and -independent. 
(A) Intracellular carnitine level in FHC cells and HCT116 cells. (B) Representative 
western blot showing OCTN2 expression in FHC and HCT116 cells with β-actin 
serves as loading control. (C) Percent change in oxygen consumption rate (OCR) 
relative to baseline in HCT116 cells treated with and without butyrate (5mM) and 
carnitine (50μM). Total contribution of butyrate toward OCR (%) is observed after 
injection of 2-deoxyglucose (2DG). (D) Area under the curve analysis from OCR 
measurements taken after 2DG injection, but before azide injection (56-84 min). 
These measurements represent butyrate oxidation (arbitrary units) at 5mM. (E) 
Percent change in OCR relative to baseline in HCT116 cells treated with and 
without butyrate (1mM) and carnitine (50μM). As before, total contribution of 
butyrate toward OCR (%) is observed after injection of 2DG. (F) Area under the 
curve analysis from OCR measurements taken after 2DG injection, but before 
azide injection (56-84 min). These measurements represent butyrate oxidation 
(arbitrary units) at 1mM. For butyrate oxidation measurements data points 
represent the average OCR (%) over 3-5 replicates per condition. Error bars are 





Figure 13 continued   
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Figure 14 Carnitine selectively affects butyrate oxidation in a dose-
dependent manner. 
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in 
HCT116 cells treated with and without butyrate (5mM) and increasing carnitine 
concentrations (12.5, 25, and 50μM). Total contribution of butyrate toward OCR 
(%) is observed after injection of 2-deoxyglucose (2DG). (B) Area under the 
curve analysis from OCR measurements taken after 2DG injection (All 
measurements after 50min). These measurements represent butyrate oxidation 
(arbitrary units) at 5mM with increasing carnitine concentrations. (C) Percent 
change in oxygen consumption rate (OCR) relative to baseline in HCT116 cells 
treated with and without SCFAs (ACE, acetate; PRO, propionate; BUT, butyrate) 
and carnitine (50μM). Final concentration for all SCFAs was 5mM. (D) Area 
under the curve analysis from OCR measurements taken after 2DG injection, but 
before azide injection (80-108 min). These measurements represent butyrate 
oxidation (arbitrary units). For butyrate oxidation measurements data points 
represent the average OCR (%) over 3-5 replicates per condition. Error bars are 





Figure 14 continued   
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Figure 15 Butyrate oxidation is CPT1A dependent. 
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in 
HCT116 cells treated with and without butyrate (5mM) and etomoxir (after 2DG 
injection). Total contribution of butyrate toward OCR (%) is observed after 
injection of 2-deoxyglucose (2DG). Effect toward blocking CPT1 is shown after 
etomoxir injection. (B) Area under the curve analysis from OCR measurements 
taken after 2DG injection, but before azide injection (82-112 min). These 
measurements represent butyrate oxidation (arbitrary units) with or without 
etomoxir injection. (C) Representative western blot of RNAi knockdown (siMock 
and siCpt1A) showing CPT1A expression over time course of 72h. CPT1A 
expression was maximally knocked down after 72h treatment. β- actin serves as 
loading control. (D) Palmitate oxidation (arbitrary units) calculated from 
subtraction of OCR measurements before and after etomoxir injection. (E) 
Percent change in OCR relative to baseline in HCT116 cells that received siMock 
or siCpt1A treated with and without 5mM butyrate. (F) Area under the curve 
analysis from OCR measurements taken after 2DG injection, but before azide 
injection (80-100 min). Measurements represent butyrate oxidation (arbitrary 
units). For butyrate oxidation measurements data points represent the average 








Figure 16 Carnitine suppressed HDAC inhibition and H3 acetylation. 
(A) HDAC activity as measured in HCT116 cells treated with or without butyrate 
and carnitine (50μM) for 1h. Average values represent three replicates per 
condition. (B) Representative western blot showing relative H3 acetylation in 
HCT116 cells treated ± butyrate (1 or 5mM final concentration) and carnitine for 
24h. (C) Quantification of H3 acetylation levels relative to total H3 levels. β-actin 




Figure 17  Impact of PDH inactivation on butyrate oxidation. 
(A) Working model of pathways that regulate butyrate oxidation. In this model, 
butyrate is oxidized by a CPT1-independent and -dependent mechanism. 
Carnitine levels and CPT1 expression are both mediators of butyrate oxidation. 
Decreased butyrate oxidation occurs as PDH becomes inactivated (through 
phosphorylation of E1) and the Warburg effect decrease OCTN2 and the 
carnitine-dependent mechanism. (B) Representative western blot showing 
phospho-PDH (Ser293) and total PDH in HCT116 cells treated ± DCA (5mM) for 
6h. β-actin was used as loading control. (C) Percent change in oxygen 
consumption rate (OCR) relative to baseline in HCT116 cells treated with and 
without butyrate (5mM) and dichloroacetate (50μM). Total contribution of butyrate 
toward OCR (%) is observed after injection of 2-deoxyglucose (2DG). (D) Area 
under the curve analysis from OCR measurements taken after 2DG injection, but 
before azide injection (74-100 min). These measurements represent butyrate 
oxidation (arbitrary units). For butyrate oxidation measurements data points 
represent the average OCR (%) over 3-5 replicates per conditions. Error bars are 









Figure 18 Carnitine-dependent mechanism is regulated through 
inactivation of PDH. 
(A) Representative western blot showing CPT1A, OCTN2, phospho-PDH 
(Ser293), and total PDH in HCT116 cells treated ± DCA (5mM) for 6. β-actin was 
used as loading control. (B) Percent change in oxygen consumption rate (OCR) 
relative to baseline in HCT116 cells treated with and without butyrate (5mM), 
carnitine (50μM), and DCA. Total contribution of butyrate toward OCR (%) is 
observed after injection of 2-deoxyglucose (2DG). (C) Area under the curve 
analysis from OCR measurements taken after 2DG injection, but before azide 
injection (88-116 min). These measurements represent butyrate oxidation 
(arbitrary units). For butyrate oxidation measurements data points represent the 





Figure 19 CPT1a expression in FHC and HCT116 cells 
(A) Western blot showing CPT1A expression in FHC and HCT116 cells. (B) 





BUTYRATE REGULATES ITS OWN METABOLIC FATE AS AN 
HDAC INHIBITOR IN COLORECTAL CANCER CELLS  
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A version of this chapter is submitted by Anna Han, Bettaieb Ahmed, Jay 
Whelan, and Dallas R. Donohoe entitled “Butyrate regulates its own metabolic 
fate as an HDAC inhibitor in colorectal cancer cells” in Journal of Cell Biology 





Colorectal cancer is characterized by a metabolic shift toward increased 
glucose utilization. Butyrate, the major energy source for non-cancerous 
colonocytes that is produced from the fermentation of fiber, is underutilized and 
its role as an HDAC inhibitor is altered in cancerous colonocytes. Understanding 
this metabolic shift is important in deciphering the protective effects derived from 
consuming a fiber diet in colorectal cancer. We discover that butyrate itself 
diminishes its own oxidation in cancerous colonocytes. This reduction in butyrate 
oxidation is associated with decreased expression of acyl-CoA dehydrogenase-
short chain (SCAD) an important component that mediates the oxidation of short-
chain fatty acids such as butyrate. Butyrate does not alter SCAD levels in non-
cancerous colonocytes. Trichostatin A, a structurally unrelated HDAC inhibitor, 
and propionate also diminish SCAD alluding to HDAC inhibition as part of the 
mechanism. Moreover, butyrate specifically inhibits HDAC1 to suppress SCAD 
expression. Knockdown of HDAC1, but not HDAC 2 or 3 abrogated the effects of 
butyrate on SCAD expression. This work identifies a mechanism by which 





Colorectal cancer (CRC) is the third most common and lethal cancer in the 
United States (Siegel, Miller, & Jemal, 2016). Considering diet is one of the 
strongest influential risk factors of CRC development, intervention of diet has 
been suggested as an effective way to decrease CRC development and mortality 
(Haggar & Boushey, 2009; Johnson et al., 2013; Vargas & Thompson, 2012). 
Many studies have observed the beneficial effect of dietary fiber against CRC, 
although some studies have reported contradicting findings (Bingham et al., 
2003; Dahm et al., 2010; Michels et al., 2000; Romaneiro & Parekh, 2012). The 
fermentation of dietary fiber in the proximal colon produces bacterial derived-
short chain fatty acids (SCFAs) including acetate, propionate and butyrate. 
Among these SCFAs, butyrate has been considered a critical metabolite that 
drives the tumor repressive effects of dietary fiber against CRC (Blackwood, 
Salter, Dettmar, & Chaplin, 2000; Macfarlane & Macfarlane, 2012; Scharlau et 
al., 2009).  
Unlike other SCFAs, butyrate is primarily metabolized by colonocytes as 
an energy source and also plays a role in epigenetic modification as a histone 
deacetylase (HDAC) inhibitor (Donohoe et al., 2011; Hamer et al., 2008; Steliou, 
Boosalis, Perrine, Sangerman, & Faller, 2012). At physiologically relevant doses, 
butyrate regulates cell proliferation, differentiation and apoptosis in colorectal 
cancer cells (Archer et al., 2005; Davie, 2003; Hinnebusch, Meng, Wu, Archer, & 
Hodin, 2002). Interestingly, the role butyrate plays in cell proliferation and 
apoptosis is related to its metabolic fates in colonocytes (Andriamihaja, 
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Chaumontet, Tome, & Blachier, 2009; Donohoe, Collins, et al., 2012). In normal 
colonocytes, butyrate is oxidized through mitochondrial β-oxidation and then 
utilized to produce energy through the tricarboxylic acid (TCA) cycle or cytosolic 
acetyl-CoA. This acetyl-CoA can be used as a cofactor for histone 
acetyltransferases (HATs) or substrates for lipogenesis (Donohoe, Collins, et al., 
2012; Rémésy, Demigne, & Morand, 1992). However, cancerous colonocytes 
favor glucose over butyrate utilization as a result of a metabolic transformation 
called the Warburg effect. This glucose-preferred environment results in 
suppressed oxidation and elevated cellular butyrate levels, which help promote 
its action as an HDAC inhibitor (Andriamihaja et al., 2009; Donohoe, Collins, et 
al., 2012). Therefore, to understand butyrate’s inhibitory and selective effect 
against CRC, the investigation regarding butyrate metabolism in cancerous 
colonocytes is crucial. 
Short chain acyl-CoA dehydrogenase (SCAD) is an enzyme that catalyzes 
the first step of butyrate mitochondrial β-oxidation in the cells (M Astbury & M 
Corfe, 2012). SCAD deletion reduces butyrate catabolism whiles simultaneously 
increasing butyryl-CoA accumulation and excretion, illustrating its role in butyrate 
metabolism (Augenlicht et al., 1999; Bhala et al., 1995; Wood et al., 1989). 
Additionally, the removal of SCAD in colonocytes leads to actual decreasing of 
butyrate oxidation (Kaiko et al., 2016). Previous studies have observed reduced 
protein expression related to mitochondrial metabolism in CRC including SCAD 
at both mRNA and protein levels (Birkenkamp-Demtroder et al., 2002; Jankova et 
al., 2011; Kim et al., 2006; Kitahara et al., 2001). However, there little is known 
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about the mechanism that controls SCAD expression. In this study, we report 
that butyrate regulates its own metabolism in colorectal cancer cells through 
suppressing SCAD expression. The mechanism as to how butyrate impacts 
SCAD levels in colorectal cancer cells is explored and appears to be mediated 
through HDAC inhibition. Importantly, non-cancerous colonocytes do not show 
this effect, thus it is selective to colorectal cancer cells.   
 
3.3 Materials and Methods 
3.3.1. Cell culture and siRNA transfection  
HCT116 cell (ATCC, CCL-247) were grown in DMEM supplemented with 
25mM glucose and 10% FBS. FHC cells (ATCC, CRL-1831) were grown in 
complete growth DMEM:F12 medium following the recommended recipe from 
ATCC with 20% FBS. RNAi transfection in HCT116 cells was performed as 
previously described (Donohoe, Collins, et al., 2012), and siRNA pools for human 
ACL (Dharmacon, #L-004915-00), human HDCA1 (Dharmacon, #L-003493-00-
0005), human HDAC2 (Dharmacon, #L-003495-02-0005), human HDCA3 
(Dharmacon, #L-003496-00-0005) and non-targeting control (Dharmacon, 
D001810-01-05) were used at a 20mM final concentration. The optimized time 
for each siRNA transfection was confirmed with Western blotting. 
3.3.2. Colonocytes isolation  
C57B1/6J were purchased from Jackson Laboratories (Bar Harbor, ME) 
and were maintained on a 12-hour light-dark cycle with free access to wather and 
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standard laboratory chow (Purina lab chow, Cat # 5001). Mouse studies were 
conducted according to federal regulations and were approved by the 
Institutional Animal Care and Use Committee at the University of Tennessee-
Knoxville. Isolation of colonic epithelial cells from mice were performed from 8-12 
weeks old male mice as previously described (Donohoe, Wali, Brylawski, & 
Bultman, 2012). Colons were washed several times with sterilized phosphate-
buffered saline (PBS). Then, the colon was incubated in PBS containing 5 mM 
EDTA (Fisher Scientific, Cat# S311-500) and 1% FBS, with or without butyrate (5 
and 10 mM), for 45 mins at 37 ℃. After 45 mins, the tissues were removed and 
isolated colonocytes were collected through centrifugation  
3.3.3. Biochemical Assays 
HDAC activity assay was performed according to manufacturer 
specifications (BioVision, Cat# K339-100). Briefely, HCT116 cells seeded into 
96well plates and treated with butyrate (Sigma, B5887) and trichostatin A 
(Promega, G6560). Following treatment times, assay was performed. All values 
were normalized to total protein in each well.  
3.3.4. Flux experiment 
To measure percentage change of oxygen consumption rates (% OCR) in 
HCT116 cells, Seahorse XF24 Analyzer (Seahorse Bioscience) was used. All 
Seahorse assays were conducted according to the company guidelines, and the 
experimental design to measure butyrate oxidation in HCT116 cells were 
followed as stated (Han et al., 2015).  HCT116 cells were seeded into XF24 cell 
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culture microplates (Seahorse Bioscience, 100777-004) with an identical cell 
number per well. Cell plates are incubated with 1X KHB (2.5 mM glucose and 50 
μM carnitine) in non-CO2 incubator at 37℃ for one hour before Seahorse assay. 
All Seahorse experiments were performed with identical conditions (unless 
otherwise stated). In brief, KHB media or sodium butyrate (Sigma, B5887) at 5 
mM final concentration were injected and the change in OCR was measured 
from baseline (% OCR). Then, 2-deoxyglucose (Sigma, D8375) was injected 
and % OCR was measured again. At last, 10% sodium azide was injected to 
block mitochondrial respiration by inhibiting complex IV, hence after azide 
injection OCR decreased at or below baseline respiration.  
3.3.5 Western blot 
From FHC, HCT116 cells and isolated colonocytes, the proteins are 
extracted with RIPA buffer (Cell Signaling, #9806), 1mM PMSF (Cell Signaling, 
#8553) and phosphatase inhibitor cocktail (Cell Signaling, #5872). 
Quantifications of protein were measured by Bradford assay. Gel electrophoresis 
and transfer were performed using standard protocol for Western blotting. 
Antibodies that were used included pan-acetylated-histone H3 (Active motif, Cat# 
39139), total Histone H3 (Active motif, Cat# 39763), total PDH (Abcam, Cat# 
ab110330), ACL (Cell Signaling, Cat # 4332), SCAD (Abcam, Cat# 154823), 
HDAC1 (Cell signaling, Cat# 34589), HDAC2 (Cell signaling, Cat# 57156), 
HDAC3 (Cell signaling, Cat# 85057) and β-actin (Sigma, Cat# A1978). 
122 
 
Chemiluminescence detection was conducted with the Odyssey Fc and bands 
were quantified with Image Studio Software (LI-COR Biosciences, Lincoln, NE). 
3.3.6. mRNA expression 
Total RNA from (un) treated HCT116 cells were extracted using Trizol 
reagent (ambion, Cat# 15596-026). The concentration and integrity of RNA were 
measured by Nano-drop 1000. Reverse transcription was performed with 
RevertAid RT kit (Thermo Scientific, Cat# K1691) by following the company’s 
protocol. The amounts of product from RT-qPCR was measured by SYBR Green 
fluorescence (applied Biosystems, Cat# 4309155). SCAD primers for isoform 1 
(Forward: GCGACTCATGGGTTCTGAAT and Reverse: 
TGCGACAGTCCTCAAAGATG), isoform 2 (Forward: 
GCCCGACTGGACCTATTTTT and Reverse: TGCGACAGTCCTCAAAGATG) 
and total (Forward: CAGGGATGGGCTTCAAGATA and Reverse: 
TGTCTGCCAACTTGAACTGG) were designed and their efficiency was 
confirmed by gel PCR. Relative gene expression levels were calculated through 
the ΔΔ Ct method and normalized to human 18S rRNA. 
3.3.7. Statistical analysis 
For biochemical assays, Seahorse experiments, and Western blotting, the 
differences between experimental groups were determined by ANOVA followed 
by a Tukey post-hoc test. All data are expressed as mean ± SEM. Groups are 





3.4.1. Butyrate diminishes its own oxidation by inhibiting SCAD expression 
in colorectal cancer cells  
In recent years our lab has sought to identify factors or conditions that 
impact the oxidation of butyrate in colorectal cancer cells. Since butyrate 
modulates gene expression through inhibiting HDACs, we postulated that 
butyrate could directly affect its own metabolic fates. To begin to test this 
possibility, HCT116 colorectal cancer cells were pretreated with or without 
butyrate (5 mM). Then, the percentage change in oxygen consumption rate (% 
OCR) was measured after 24 hours. In pretreated cells, butyrate repressed its 
own oxidation (Figure 20A). In order to inhibit glucose oxidation resulting in OCR 
values only contributed by butyrate, 2-deoxyglucose (2DG), which blocks glucose 
utilization was injected. After 2DG injection, butyrate oxidation was significantly 
lower in pretreated cells as compared to non-pretreated controls (Figure 20B). 
Butyrate is transported into the colonocyte via a monocarboxylate transporter-1 
(MCT1), where it taken up into the mitochondria and oxidized through carnitine-
dependent and independent mechanisms (Han et al., 2015). After butyrate 
moves into the mitochondria, short chain acyl-CoA dehydrogenase (SCAD) 
catalyzes the first dehydrogenation step of butyryl-CoA to produce acetyl-CoA (M 
Astbury & M Corfe, 2012) (Figure 20C). Western blot analysis of colorectal 




3.4.2. Butyrate reduces SCAD expression only in colorectal cancer cells  
Butyrate decreased the expression of SCAD in colorectal cancer cells; 
however, it was not clear whether butyrate would have this same effect in non-
cancerous colonocytes. Cancerous colonocytes have a reduced ability to oxidize 
butyrate compared to non-cancerous colonocytes which result in part from lower 
cellular carnitine levels and reduced protein expression related to carnitine-
dependent mechanisms, such as organic cation/carnitine transporter, OCTN2 
and carnitine palmitoyltransferase, CPT1A (Han et al., 2015). Thus, the reduced 
ability of cancerous colonocytes to oxidize butyrate may be due to the reduced 
SCAD levels compared to the non-cancerous colonocytes. To begin to address 
this, we compared SCAD levels in cancerous (HCT116 cells) and non-cancerous 
(FHC cells) colonocyte lines. To our surprise, SCAD expression was actually 
higher in HCT116 cells than FHC cells (Figure 21A). This may be due to the fact 
that the expression and activity of enzymes that related to fatty acid metabolism 
(i.e. SCAD) are dramatically elevated after birth in tissues that strongly 
metabolize fatty acids (Nagao, Parimoo, & Tanaka, 1993). Since FHC cells 
originated from a 13-week fetus, we concluded that the FHC cells are not a 
representative cell line for non-cancerous colonocytes. However, using a primary 
colonocytes,  Kaiko et al. (2011) confirmed that normal colonocytes have high 
SCAD expression compared to the stem cells in the colonic crypts (Kaiko et al., 
2016). 
Cancerous colonocytes increase aerobic glycolysis (utilize the Warburg 
effect), which may after the expression of proteins such as SCAD and impact the 
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oxidation of butyrate. To directly test the importance of the Warburg effect in 
butyrate-mediated SCAD reduction, we cultured cells in media with varying 
glucose concentrations; high (25 mM) or low (0.5 mM). Lower SCAD expression 
was observed in the HCT116 cells under both high (the Warburg effect) and low 
glucose condition (suppressed the Warburg effect) (Figure 21B and Figure 25). 
However, only high glucose condition led to a significant decrease in SCAD 
expression (Figure 21B and 21C). Throughout this paper (unless otherwise 
mentioned), pyruvate dehydrogenase (PDH) is used as a loading control instead 
of β-Actin due to the fact that PDH is also a mitochondrial protein like SCAD, and 
its expression is not affected by butyrate in cancerous colonocytes. Based on the 
importance of the Warburg effect, non-cancerous colonocytes were isolated from 
C57BL/6J wild type mice to test whether butyrate’s influence SCAD expression in 
normal colonocytes that are not undergoing the Warburg effect. While butyrate 
decreases SCAD expression in the colorectal cancer cells, normal isolated 
colonocytes showed a trend toward increasing SCAD expression, but this was 
not statistically significant (Figure 21D and 21E). Since butyrate also increases 
PDH expression in the normal isolated colonocytes, we normalized SCAD 
expression with β-Actin (Figure 26).  
To confirm whether butyrate suppressed SCAD at the mRNA level, we 
conducted qRT-PCR with all isoforms of Scad (Scad1 and Scad2) and total 
Scad. At a high dose (5 mM), butyrate significantly reduced mRNA levels for 
Scad1, Scad2, and total Scad in HCT116 cells (Figure 22). Additionally, at a low 
butyrate concentration (1 mM), Scad2 and total Scad mRNA levels were 
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significantly decreased. These data suggest that butyrate suppresses SCAD 
expression at the transcriptional levels in the colorectal cancer cells, which may 
involve HDAC inhibition.  
3.4.3. Butyrate mediates SCAD expression as an HDAC inhibitor, not as a 
metabolite 
 The fermentation of dietary fiber in the colon produces additional SCFAs, 
which include acetate and propionate. Therefore, we sought to investigate 
whether these other SCFAs reduced SCAD expression in colorectal cancer cells 
like butyrate. Both propionate and butyrate significantly suppress SCAD 
expression, while acetate does not influence SCAD expression in HCT116 cells 
(Figure 23A and 23B). Along with butyrate, propionate has been shown to be an 
HDAC inhibitor (Aoyama, Kotani, & Usami, 2010). This alludes to HDAC 
inhibition as a key component in regulating SCAD expression in colorectal cancer 
cells.   
Butyrate is involved in epigenetic modifications through two mechanisms 
(Figure 23C) (Donohoe, Collins, et al., 2012). Mitochondrial butyrate oxidation 
results in the biogenesis of Acetyl-CoA, which can be utilized as a cofactor for 
HATs through ATP-citrate lyase (ACL). In addition, butyrate directly goes into the 
nucleus where it functions as an HDAC inhibitor. First, to test the importance of 
HDAC inhibition, a structurally distinct HDAC inhibitor, trichostatin A (TSA), was 
used as a positive control. Both butyrate and TSA significantly reduced SCAD 
expression (Figure 23D and 23E). Next, a siRNA knockdown of ACL was 
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performed and SCAD expression was evaluated with and without butyrate. Since 
ACL catalyzes the reaction that converts citrate into acetyl-CoA in the cytosol, an 
ACL knockdown would block butyrate’s involvement as a HAT cofactor. 
However, knockdown of ACL did not impact SCAD suppression caused by 
butyrate, indicating that this mechanism is unrelated to SCAD regulation. There 
was no difference in the percentage change in OCR between siMock and siACL 
transfected cells (Figure 27A and 27B). In addition, ACL knockdown did not alter 
SCAD expression compared to siMock HCT116 cells, while butyrate still 
significantly reduced SCAD expression in the both conditions (Figure 27C). 
Taken together, this data point to HDAC inhibition as the major mechanism as to 
how butyrate regulates SCAD expression in the colorectal cancer cells.  
3.4.4. Butyrate decreases SCAD levels through selective inhibition of 
HDAC1 in colorectal cancer cells 
In CRC, HDAC 1, HDAC 2, and HDAC 3 are highly expressed in order to 
accelerate cell proliferation, growth and survival (Weichert et al., 2008; Wilson et 
al., 2006). In general, butyrate effectively inhibits most HDACs resulting in 
decreased cell proliferation and induction of cell apoptosis in the cancer cells 
(Davie, 2003; Donohoe, Collins, et al., 2012). Although we found that butyrate 
suppresses SCAD levels through HDAC inhibitor action, it was still unclear 
whether a specific HDAC was involved in regulating SCAD level. Therefore, 
HDAC1, HDAC2, or HDAC3 were knocked down by RNAi and these cells were 
treated with butyrate to test whether butyrate-induced SCAD reduction was 
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augmented with each selective knockdown condition. While butyrate and TSA 
significantly decreased SCAD levels in siMock cells, siHDAC1 transfected cells 
did not shown decreased SCAD levels after butyrate treatment (Figure 24A and 
24B). RNAi knockdown of HDAC2 and HDAC3 in HCT116 cells did not impact 
SCAD levels like as HDAC1 (Figure 28). These findings demonstrate that 
butyrate targets HDAC1 to suppress SCAD levels in the colorectal cancer cells. 
 
3.5 Discussion 
Normal colonocytes prefer to oxidize butyrate as a primary energy source 
whereas cancerous colonocytes increases glucose utilization, which is 
demonstrated through increased flurodeoxyglucose (FDG) uptake as measured 
by Positron Emission Tomography – Computed Tomography (PET-CT) (de 
Geus-Oei et al., 2006; Delbeke & Martin, 2011; Miles, 2015; Roediger, 1980). In 
addition, colorectal cancer cells display a reduced capacity to oxidize butyrate 
compared to normal colonocytes, which could result from diminished intracellular 
carnitine, and CPT1A levels (Han et al., 2015). These metabolic alterations 
significantly impact butyrate’s role as an HDAC inhibitor in colorectal cancer 
(Donohoe, Collins, et al., 2012). As an HDAC inhibitor, butyrate represses cell 
proliferation and induces cell death in colorectal cancer cells (Archer et al., 2005; 
Archer, Meng, Shei, & Hodin, 1998; Medina et al., 1997). Thus, gaining 
knowledge toward the mechanisms that regulate butyrate oxidation in cancer 
cells is an important step in understanding butyrate’s role as an HDAC inhibitor, 
which is associated with protective action of butyrate against CRC. Here, we 
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demonstrated that butyrate suppresses its own oxidation in cancerous 
colonocytes through the regulation of SCAD levels, a critical enzyme in the 
oxidation of butyrate. Butyrate decreases SCAD levels as an HDAC inhibitor. 
Specifically, SCAD is regulated via HDAC1.  
Many studies have reported the role of SCAD in regulating butyrate 
oxidation (Bhala et al., 1995; M Astbury & M Corfe, 2012; Wood et al., 1989). 
SCAD contributes to energy maintenance in the colon via participating in SCFA  
oxidation (Augenlicht et al., 1999). Recently, it was reported that colonocytes 
isolated from SCAD-/- mice showed diminished butyrate oxidation compared to 
those from control WT mice (SCAD+/+), which confirms the importance of SCAD 
in mediating butyrate oxidation in colonocytes (Kaiko et al., 2016). In contrast to 
this study, a cancerous colonocyte cell line was used due to previous reports 
demonstrating diminished butyrate oxidation in this cell line (Donohoe, Collins, et 
al., 2012; Han et al., 2015). The fact that butyrate reduces its own oxidation in 
these cells reveals a potential mechanism as to why colorectal cancer cells are 
sensitive to butyrate’s HDAC inhibitory effects.  
This mechanistic relationship between butyrate and SCAD in the 
colorectal cancer cells was significantly influenced by the Warburg effect. 
Previously, it was found that butyrate (1 mM) increased SCAD expression in a 
colorectal cancer cell line (HT15), however similar to a non-cancerous cell line, 
these cells still preferentially utilized butyrate over glucose thereby negating the 
impact of the Warburg effect (Serpa et al., 2010). The colonic administration of 
butyrate in healthy subjects increases gene transcription relating to energy 
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metabolism and fatty acid metabolism, while SCAD was not altered (Vanhoutvin 
et al., 2009). Germfree mice, which lack a microbiome and the capability to 
produce butyrate from fiber, show reduced SCAD expression compared to 
normal mice (Donohoe et al., 2011). Their findings are consistent with butyrate 
modulating SCAD levels differently in non-cancerous colonocytes.  
In general, butyrate inhibits most HDACs, except class 2 (HDAC 6 and 10) 
and class 3, and specifically inhibits HDAC 1 and 3 in colorectal cancer cells 
(Davie, 2003; Thangaraju, Carswell, Prasad, & Ganapathy, 2009). As an HDAC 
inhibitor, butyrate effectively impedes cancer cell survival and growth (Bultman, 
2014; Davie, 2003). In addition, butyrate suppresses intestinal inflammation and 
oxidative stress, while also protecting the intestinal epithelial barrier via its HDAC 
inhibitor roles; there are likely to help reduce CRC susceptibility (Canani, Di 
Costanzo, & Leone, 2012; Leonel & Alvarez-Leite, 2012; Plöger et al., 2012). 
Separate from the non-cell autonomous effects, butyrate availability can 
influence cancerous colonocyte metabolism and HDAC inhibition. The 
suppressive action of butyrate on SCAD expression and its own oxidation in the 
colorectal cancer cells is mediated by its function as an HDAC inhibitor. Butyrate 
specifically inhibits HDAC1 to have these regulatory actions as knockdown of this 
protein negates any changes in SCAD caused by butyrate. These data also 
allude to butyrate promoting its own action as an HDAC inhibitor in colorectal 
cancer cells through altering suppressing its own metabolism. It will be 
interesting to conduct further research regarding why butyrate behaves in this 
way and whether this mechanism helps mediate its specificity toward cancer 
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cells. CRC (all stages) has altered gene expression characterized by lower 
mitochondrial metabolism and a down-regulation in SCAD expression 
(Birkenkamp-Demtroder et al., 2002; Kitahara et al., 2001). Future studies are 
need to investigate the outcome of reduced SCAD expression in cancerous 
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Figure 20 Butyrate suppresses its own oxidation by inhibiting SCAD 
expression in colorectal cancer cells. 
(A) Percentage change in oxygen consumption rate (OCR) relative to baseline in 
pre-treated HCT116 cells with and without butyrate (5 mM, 24 hrs). (B) Area 
under the curve measurement from OCR analysis taken after 2DG injection but 
before azide injection (56-104 min). (C) Schematic diagram of butyrate oxidation 
in the cancerous colonocytes. Cancerous colonocytes oxidize butyrate through 
carnitine-dependent and/or independent pathway. In the mitochondria, SCAD 
plays a role in first step of butyrate β-oxidation.  (D) Western blot confirming the 
reduced SCAD level by butyrate. Data for butyrate oxidation measurement 
represent the average OCR (%) over 3-5 replicates per condition. Error bars are 
± SEM. MCT1; monocarboxylate transport protein 1, OCTN2; organic 
cation/carnitine transporter, ACSS; Acyl Co-A synthetases, CPT1/2; carnitine 





Figure 20 continued   
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Figure 21 Butyrate reduces SCAD expression in colorectal cancer cells. 
(A) Western blot showing SCAD expression in FHC cells (non-cancerous 
colonocytes) and HCT116 cells (colorectal cancer cells). (B) Western blot 
describing SCAD expression in FHC cells and HCT116 cells that were treated 
with (0 mM, CON) or without butyrate (5 mM, B5). HCT116 cells were grown 
under the absence (2.5 mM glucose) and presence (25 mM glucose) for the 
Warburg effect. (C) Quantification of SCAD levels relative to PDH levels. (D) 
Western blot showing SCAD levels in isolated normal colonocytes with butyrate 
(0 mM, CON; 5 mM, B5 and 10 mM. B10). (E) Quantification of SCAD expression 
relative to β-actin levels. For statistical analysis, western blot was conducted 
three times per condition. Error bars are Mean ± SEM. *p<0.05 indicates 









Figure 22 Butyrate reduces the mRNA levels of SCAD in colorectal cancer 
cell. 
(A) mRNA expression of isoform 1, isoform 2 and total SCAD was evaluated by 
semi-quantitative RT-PCR (0 mM, CON; 5 mM, B5 and 10 mM, B10). The 
relative mRNA level was normalized to 18S rRNA and shown as fold of the 
control value. For statistical analysis, qRT-PCT was conducted three times per 
condition. Error bars are Mean ± SEM. *p<0.05 and **p<0.01 indicates significant 




Figure 23 Butyrate mediates SCAD expression as an HDAC inhibitor in 
colorectal cancer cells 
(A) Western blot showing SCAD expression in HCT116 cells that were treated 
with a set of SCFAs (ACT; acetate, PRO; propionate, BUT; butyrate and APB; all 
of SCFAs) at 5 mM. (B) Quantification of SCAD levels relative to PDH levels. (C) 
A figure of mechanisms that butyrate plays in epigenetic role in colonocytes. In 
this figure, butyrate acts as a co-factor for HATs through the involvement of ATP-
citrate lyase (ACL). Also, butyrate directly inhibits HDACs. (D) Western blot 
describing SCAD expression in HCT116 cells that were treated with butyrate (5 
mM) or TSA (1 μM). (E) Quantification of SCAD expression relative to PDH 
levels. For statistical analysis, western blot was conducted three times per 
condition. Error bars are Mean ± SEM. *p<0.05 and **p<0.01 indicates significant 










Figure 24 Butyrate selectively inhibits HDAC 1 to reduce SCAD expression 
in colorectal cancer cells. 
(A) Western blot showing SCAD expression in siMock and siHDAC1 transfected 
HCT116 cells after treatment without butyrate and with butyrate (5 mM) or TSA 
(1 μM) for 6hrs. (B) Quantification of SCAD levels relative to PDH levels. For 
statistical analysis, western blot was conducted three times per condition. Error 
bars are Mean ± SEM. *p<0.05 indicates significant difference between cells 





Figure 25 The Warburg effect involves in SCAD levels in colorectal cancer 
cells. 
(A) Western blot showing SCAD expression in FHC cells (non-cancerous 
colonocytes) and HCT116 cells (colorectal cancer cells) with or without Warburg 
effect. (B) Quantification of SCAD levels relative to PDH levels. For statistical 







Figure 26 Butyrate increases PDH levels in normal isolated colonocytes. 
Quantification of PDH expression relative to β-actin levels. For statistical 






Figure 27 Butyrate does not regulate SCAD expression as a metabolite in 
colorectal cancer cell. 
(A) Percent change of oxygen consumption rate (OCR) relative to baseline in 
siACL and siMock transfected HCT116 cells. OCR (%) after 2DG injection is total 
contribution of butyrate. (B) Area under the curve analysis from percentage 
change in OCR of siMock and siACL transfected HCT116 cells with and without 
butyrate (5 mM). OCR measurement taken after 2DG injection, but before 
etomoxir (ETO) injection (48-72 mins) (C) Western blot presenting SCAD levels 
siMock and siACL transfected HCT116 cells after treatment of butyrate or not. 
Data for butyrate oxidation measurement represent the average OCR (%) over 3-
5 replicates per condition. Error bars are ± SEM. For statistical analysis, western 




Figure 28 HDAC 2 and HDAC 3 are not involved in SCAD suppression by 
butyrate in colorectal cancer cells. 
(A) Western blot presenting SCAD levels in siMock and siHDAC2 transfected 
HCT116 cells after treatment without butyrate and with butyrate (5 mM) or TSA 
(1 μM) for 6 hrs.  (B) Quantification of SCAD levels relative to PDH levels. (C) 
Western blot showing SCAD levels in siMock and siHDAC3 transfected HCT116 
cells after pre-treatment without butyrate and with butyrate (5 mM) or TSA (1 
μM).  (D) Quantification of SCAD levels relative to PDH levels. For statistical 
analysis, western blot was conducted three times per condition. Error bars are 
Mean ± SEM. *p<0.05 indicates significant difference between cells treated with 




CONCLUSION AND FUTURE DIRECTION 
In this dissertation, it has been presented (1) the capacity of butyrate 
oxidation is reduced in cancerous colonocytes compared to non-cancerous 
colonocytes; (2) butyrate is oxidized in the colorectal cancer cells by both a 
carnitine-dependent and -independent mechanisms at physiologically relevant 
levels, which are selective for butyrate only among other SCFAs oxidation; (3) 
carnitine-dependent butyrate oxidation mechanism is suppressed in colorectal 
cancer cells through PDH inhibition; (4) butyrate decreases its own oxidation by 
suppressing SCAD expression in cancerous colonocytes; (5) butyrate functions 
as an HDAC inhibitor and selectively inhibits HDAC 1 in order to reduce SCAD 
levels and its own oxidation in colorectal cancer cells . 
Our findings bring a better understanding of butyrate metabolism in 
cancerous colonocytes that allows insight into why butyrate has selective and 
inhibitory effects against colorectal cancer cells. Moreover, we report here for the 
first time that butyrate is involved in its own oxidation by specifically inhibiting 
HDAC1.  
In the future, the studies of the effect of carnitine supplementation on 
colorectal cancer by using animal model and/or human study would be needed to 
test the results using in vitro models suggested in chapter II. Dietary sources with 
high carnitine (i.e. red meat) have shown an increased susceptibility of CRC 
development. Based on our findings in chapter II, the consumption of high 
carnitine dietary sources (i.e. red meat) might increase butyrate oxidation 
resulting in reduced HDAC inhibition and subsequently reduce butyrate’s 
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protective effects against CRC. Successful animal and/or human studies will offer 
a justification of butyrate’s selective and protective effects toward CRC. 
Moreover, based on the conclusions of chapter III, we need to answer why 
butyrate regulates its own oxidation in cancerous colonocytes. This future studies 
will suggest another mechanism whereby butyrate shows anti-cancer effects 
toward CRC. Also, investigating role of SCAD in butyrate oxidation in cancerous 
colonocytes would be helpful to explain why cancerous colonocytes have 
reduced butyrate oxidation capability compared to non-cancerous colonocytes 
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